1/3 62

10/ 071,483

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 43	Jun 06	PASCAL enhanced with additional data

10/ 071,483

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:04:02 ON 07 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:04:07 ON 07 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 JUN 2003  HIGHEST RN 526915-11-7
DICTIONARY FILE UPDATES:    6 JUN 2003  HIGHEST RN 526915-11-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10071483c.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
```

10/ 071,483

```
=> s l1 ful
FULL SEARCH INITIATED 10:04:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   9684 TO ITERATE

100.0% PROCESSED    9684 ITERATIONS                          362 ANSWERS
SEARCH TIME: 00.00.01

L2          362 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               148.15     148.36

FILE 'CAPLUS' ENTERED AT 10:04:46 ON 07 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 7 Jun 2003  VOL 138 ISS 24
FILE LAST UPDATED: 6 Jun 2003  (20030606/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3          42 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 42 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 42  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2002:946063  CAPLUS
DOCUMENT NUMBER:          138:14078
TITLE:                    Preparation of hybrid 2-aminotetralin and
                          aryl-substituted piperazine compounds and their use in
                          altering CNS activity
INVENTOR(S):              Dutta, Aloke K.
PATENT ASSIGNEE(S):       Wayne State University, USA
SOURCE:                   PCT Int. Appl., 49 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002098367      A2   20021212       WO 2002-US18267  20020607
     WO 2002098367      A3   20030123
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-296622P P 20010607
OTHER SOURCE(S): MARPAT 138:14078

GI



I



II

AB Hybrid compds. of formula I [R = H, alkyl, alkoxy, CN, etc.; R1 = alkyl, alkenyl, alkynyl, etc.; m = 0-1; n = 0-4; p = 1-4; A = heterocyclic arom. ring; XY = (substituted) 5 or 6 membered arom. ring], contg. an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidine moiety, are prepd. which exhibit high levels of CNS activity, in some cases exhibiting esp. high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes. Thus, II was prepd. from 1-phenylpiperazine, N-(2-bromoethyl)phthalimide, 7-methoxytetralone and propionyl chloride. The prepd. compds. had relatively high affinity for the D2, D3 and D4 receptor subtypes.

IT **444145-86-2P 444145-88-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of hybrid 2-aminotetralin and aryl-substituted piperazine compds. for altering CNS activity)

RN 444145-86-2 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]-2-propynylamino]- (9CI) (CA INDEX NAME)



RN 444145-88-4 CAPLUS

10/ 071,483

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]propylamino]- (9CI) (CA INDEX NAME)



IT **444145-95-3P 477789-03-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hybrid 2-aminotetralin and aryl-substituted piperazine compds. for altering CNS activity)

RN 444145-95-3 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]propylamino]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 477789-03-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]-2-propynylamino]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

IT **444145-80-6P 474655-18-0P 477788-85-5P 477788-86-6P 477788-87-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of hybrid 2-aminotetralin and aryl-substituted piperazine compds. for altering CNS activity)

RN 444145-80-6 CAPLUS
CN 1-Piperazineethanamine, 4-phenyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

10/ 071,483



RN 474655-18-0 CAPLUS
CN 1,2-Ethanediamine, N-[4-(4-phenyl-1-piperazinyl)butyl]-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 477788-85-5 CAPLUS
CN 1-Piperazineethanamine, 4-phenyl-N-2-propynyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 477788-86-6 CAPLUS
CN Propanamide, N-[2-(4-phenyl-1-piperazinyl)ethyl]-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 477788-87-7 CAPLUS
CN 1-Piperazineethanamine, 4-phenyl-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2003 ACS

10/ 071,483

ACCESSION NUMBER: 2002:116961 CAPLUS
DOCUMENT NUMBER: 137:125135
TITLE: A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors
AUTHOR(S): Dutta, Aloke K.; Fei, Xiang-Shu; Reith, Maarten E. A.
CORPORATE SOURCE: Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, 48202, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 619-622
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:125135
GI



I

AB Title compds. such as I (R = MeO, OH; R1 = propargyl, Pr; R2 = H, Cl; n = 2, 4) were prepd. Our preliminary study revealed that the affinity of I for the D2 and D3 receptors depended significantly on n. Further structure-activity studies led to a novel template showing 50- to 100-fold selectivity for the D3 receptor.

IT **444145-86-2P 444145-88-4P 444145-93-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of hybrid compds. derived by combining 2-aminotetralin and piperazine fragments and their binding activity at D2 and D3 receptors)

RN 444145-86-2 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]-2-propynylamino]- (9CI) (CA INDEX NAME)



RN 444145-88-4 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]propylamino]- (9CI) (CA INDEX NAME)



10/ 071,483

RN 444145-93-1 CAPLUS
CN 2-Naphthalenol, 7-[[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]propylamino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



IT **444145-80-6P 474655-18-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of hybrid compds. derived by combining 2-aminotetralin and piperazine fragments and their binding activity at D2 and D3 receptors)
RN 444145-80-6 CAPLUS
CN 1-Piperazineethanamine, 4-phenyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 474655-18-0 CAPLUS
CN 1,2-Ethanediamine, N-[4-(4-phenyl-1-piperazinyl)butyl]-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



IT **444145-95-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of hybrid compds. derived by combining 2-aminotetralin and piperazine fragments and their binding activity at D2 and D3 receptors)
RN 444145-95-3 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-7-[[2-(4-phenyl-1-piperazinyl)ethyl]propylamino]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:565003 CAPLUS
DOCUMENT NUMBER: 135:152714
TITLE: Preparation of aromatic amines and amides useful as melanocortin receptor agonists and antagonists
INVENTOR(S): Lundstedt, Torbjoern; Skottner, Anna; Seifert, Elisabeth; Andersson, Per; Kaulina, Larisa; Dikovskaya, Klara; Mutule, Ilze; Mutulis, Felikss; Wikberg, Jarl; Starchenkov, Igor; Kreicberga, Jana
PATENT ASSIGNEE(S): Melacure Therapeutics AB, Swed.; Pett, Christopher Phineas; et al.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055107	A2	20010802	WO 2001-GB356	20010129
WO 2001055107	A3	20020117		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-2056 A 20000128
GB 2000-2058 A 20000128
OTHER SOURCE(S): MARPAT 135:152714

AB The present invention relates to arom. amines and amides (I; B-E-N(R)-X-F-A and pharmacol. active salts thereof) and to the use of these compds. for the treatment of obesity, anorexia, inflammation, mental disorders and other diseases assocd. with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones. In I: X is carbonyl, methylene or is absent (i.e. it is a single bond); E and F are independently a satd. or unsatd., straight or branched chain acyclic hydrocarbon group having 1-10 C atoms, or E and/or F may be absent. R is -P-R4, -C(O)-D-R' (P and D are independently a satd. or unsatd., straight or branched chain acyclic hydrocarbon group having 1-10 C atoms; or D is absent (i.e. D is a single bond); R4 is hydroxy, cyclohexyl, cyclopentyl, guanidine, aminoguanidine, carboxy; R' is hydroxy, Me, cyclohexyl, cyclopentyl, guanidine, aminoguanidine, carboxy; or R4 or R' = (possibly

substituted) amino, carbamoyl, alkoxy, alkoxycarbonyl, acyl, morpholinyl, pyrrolidinyl, piperidinyl; or R4 may be A and B as defined below). A and B are the same or different and are (possibly substituted) quinolinyl, imidazolyl, pyrazinyl, isoquinolinyl, cyclopentadienyl, pyridinyl, Ph, pyrimidinyl, pyrrolyl, isoindolyl, naphthyl, indolyl, indenyl. Several claimed compds. (N-(3-aminopropyl)-3-(1H-indol-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)propionamide, N-(5-aminopentyl)-N-(2-chloro-3-phenylallyl)-4-(1H-indol-3-yl)butyramide, [2-(1H-indol-3-yl)ethyl]bis(3-phenylpropyl)amine hydrochloride, 4-guanidino-N-[2-(1H-Indol-3-yl)ethyl]-N-(4-methoxybenzyl)butyramide hydrochloride) were tested (results given) for affinity for melanocortin receptors (MC1, MC3, MC4, MC5) and/or influence on cAMP. Anti-inflammatory effects were tested (results given) for [2-(1H-indol-3-yl)ethyl]bis(3-phenylpropyl)amine hydrochloride. Also claimed is a process for the prodn. of the claimed compds. wherein R-Y is reacted with B-E-NH-X-F-A, preferably using a std. N-alkylation procedure. Two example prepns. are given. In one example, to a soln. of 4-N-benzylbutylguanidine (10 mmol) in MeCN (15 mL) under stirring was added 1,3-bis(benzyloxycarbonyl)-2-methylthiopseudourea (10 mmol). Stirring was continued for 24 h at room temp., the reaction mixt. concd. in vacuo, purified by chromatog. (silica gel; Et acetate) to give a viscous oil (90 %). To a soln. of the above oil (N-(4-benzylaminobutyl)-N',N''-bis(benzyloxycarbonyl)guanidine) (0.5 mmol) and 3-(1H-indol-3-yl)propionic acid 2,5-dioxopyrrolidin-1-yl ester (0.5 mmol) in MeCN (10 mL) under stirring satd. $NaHCO_3$ soln. until pH 9 was added, stirred for 2 days at room temp., evapd. in vacuo. The residue was dissolved in Et acetate (12 mL), washed with H_2O (2x5 mL), dried ($MgSO_4$) and evapd. in vacuo. To the crude intermediate dissolved in EtOH (10 mL), 5% Pd/C (20 mg) and 4 drops of concd. HCl were added and hydrogenated for 1 h at ambient pressure; the Pd catalyst was filtered off, the soln. evapd. in vacuo, and the residue purified by chromatog. (silica gel; chloroform-MeOH-H_2O, 120:20:1) to give N-benzyl-N-(4-guanidinobutyl)-2-(1H-indol-3-yl)acetamide hydrochloride (47 %) as a colorless foam.

IT **352292-02-5P 352292-04-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arom. amines and amides useful as melanocortin receptor agonists and antagonists)

RN 352292-02-5 CAPLUS

CN 1H-Indole-3-acetamide, N-(2-aminoethyl)-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 352292-04-7 CAPLUS

CN 2-Naphthaleneacetamide, N-(2-aminoethyl)-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:380551 CAPLUS
DOCUMENT NUMBER: 135:5616
TITLE: Preparation of hydrazone compounds and pesticides
INVENTOR(S): Mita, Takeshi; Ohtsu, Tadashi; Hotta, Hiroyasu; Io, Tomoaki; Ueno, Hideki; Masuzawa, Yoshihide; Miyake, Toshiro; Mimori, Norihiko; Takii, Shinji; Itoh, Toshinori
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 409 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036381	A1	20010525	WO 2000-JP8016	20001114

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
JP 1999-323698 A 19991115
JP 1999-323699 A 19991115
JP 2000-298021 A 20000929
JP 2000-301562 A 20001002

OTHER SOURCE(S): MARPAT 135:5616
GI



I

AB Hydrazone compds. such as hydrazono-1,2,3,4-tetrahydronaphthalene, hydrazonoindoline, or hydrazochroman, resented by general formula (I) or salts thereof [wherein A = CH2, CH2CH2, OCH2, S(O)pCH2, S(O)pCH2CH2, or CH2 S(O)pCH2 (wherein p = 0-2), N-(un)substituted NHCH2, NHCH2CH2, or CH2NHCH2, (CH2)3, OCH2CH2; B = a single bond, O, S, (un)substituted NH, CO; G = -N:C(R5)NR6R7 (G-1), -N(R8)C(:W2)Q2 (G-2), -N:C(R5)W3-R9 (G-3); when B = O, S, (un)substituted NH, CO, G-1, or G-3, then Q1 = (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, (un)substituted Ph, arom. or aliph. heterocyclyl, etc.; when B = a single bond and G = G-2, then Q1 = (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, etc.; when B = a single bond or (un)substituted NH, then Q1 = H; Q2 = H, (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, alkoxycarbonyl, (un)substituted benzoyl or Ph, arom. or aliph. heterocyclyl, etc.; W1, W2 = O, S; W3 = O, S, CH2; X = H, halo, cyano, isocyanato, NO2, N3, CHO, CO2H, (un)substituted carbamoyl, OH, SH, etc.; R1 = H, (halo)alkyl, cycloalkyl, cycloalkylalkyl, (halo)alkoxyalkyl, alkoxyalkoxyalkyl, benzyloxyalkyl, (halo)alkylthioalkyl, etc.; R2 = H, (halo)alkyl, alkoxyalkyl, alkylthioalkyl, cyanoalkyl, alkoxycarbonyl, (halo)alkenyl,

10/ 071,483

etc.; m = 1-4] are prepd. Novel agricultural chems., in particular, insecticides and miticides contg. these compds. as the active ingredient formula I are also claimed. Thus, a soln. of tert-Bu 6-chloro-1-hydrazono-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate and N,N-dimethylacetamide di-Me acetal in toluene was refluxed for 4 h to give tert-Bu 6-chloro-1-[1-(dimethylamino)ethylidenehydrazono]-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate (II). II at 500 ppm controlled .gtoreq.80% Spodoptera litura larvae on cabbage leaves.

IT **340823-17-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydrazone compds. such as hydrazonotetrahydronaphthalene, hydrazonoindoline, or hydrazochroman derivs. as miticides and insecticides)

RN 340823-17-8 CAPLUS

CN Cyclohexanecarboxamide, N-[1-[[1-(dimethylamino)ethylidene]hydrazono]-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:101127 CAPLUS
DOCUMENT NUMBER: 134:162920
TITLE: Preparation of aromatic amines and amides as ligands for neuropeptide Y Y5 receptors useful in the treatment of obesity and other disorders
INVENTOR(S): Dax, Scott L.; Mcnally, James; Youngman, Mark
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009120	A1	20010208	WO 2000-US20482	20000727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6380224	B1	20020430	US 2000-626856	20000727
EP 1202986	A1	20020508	EP 2000-952233	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL
BR 2000012804 A 20020806 BR 2000-12804 20000727
JP 2003506367 T2 20030218 JP 2001-514323 20000727
NO 2002000384 A 20020322 NO 2002-384 20020124
US 2002115715 A1 20020822 US 2002-71483 20020207
PRIORITY APPLN. INFO.: US 1999-146069P P 19990728
US 2000-626856 A3 20000727
WO 2000-US20482 W 20000727
OTHER SOURCE(S): MARPAT 134:162920

GI



I

AB Title compds. [I; R1 = H, OH, halo, trifluoroalkyl, cycloalkyl, NO2, amino, (substituted) alkyl, alkoxy, alkylthio, etc.; n = 1, 2; m = 0-3; B1, B2 = H; B1B2 = CH2; R2 = H, OH, halo, alkyl, alkenyl, cycloalkyl, (substituted) Ph, naphthyl, PhO, heteroaryl, heterocyclyl; L = alkylene, alkenylene, alkynylene, cycloalkylene, arylalkylene, .alpha.-aminoalkylene, piperidin-4-ylmethylene, piperazine-1-ylmethylene, etc.; Y = CH2, CO; Z = aryl, sulfonamido, arylsulfonamido, arylamido, arylureido, arylacetamido, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl], were prepd. Thus, 1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthaleneamine bishydrochloride (prepn. given), N.alpha.-tert-butoxycarbonyl-N.omega.-2-fluorobenzenesulfonyl-L-lysine (prepn. given), diisopropylethylamine, and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate were stirred in DMF to give the amide coupling product as a mixt. of diastereomers. The mixt. was deprotected with CF3CO2H followed by redn. with BH3.THF to give N-[5-amino-6-[[cis-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluorobenzenesulfonamide trihydrochloride. The latter at 3 .mu.M gave 100% inhibition of binding of 125I-PYY binding to human NPY Y5 receptors.

IT **261715-55-3P 324755-30-8P 324755-31-9P**
324755-32-0P 324755-33-1P 324755-34-2P
324755-35-3P 324755-36-4P 324755-37-5P
324755-38-6P 324755-39-7P 324755-46-6P
324755-47-7P 324755-48-8P 324755-49-9P
324755-50-2P 324755-58-0P 324755-59-1P
324755-60-4P 324755-80-8P 324755-81-9P
324755-82-0P 324755-84-2P 324755-85-3P
324755-86-4P 324755-87-5P 324755-88-6P
324755-89-7P 324755-93-3P 324755-94-4P
324755-95-5P 324755-97-7P 324756-12-9P
324756-13-0P 324756-14-1P 324756-15-2P
324756-16-3P 324756-17-4P 324756-18-5P
324756-19-6P 324756-20-9P 324756-21-0P
324756-32-3P 324756-33-4P 324756-34-5P
324756-35-6P 324756-36-7P 324756-40-3P
324756-41-4P 324756-42-5P 324756-43-6P
324756-44-7P 324756-45-8P 324756-47-0P
324756-48-1P 324756-49-2P 324756-51-6P
324756-53-8P 324756-54-9P 324756-55-0P
324756-56-1P 324756-57-2P 324756-58-3P
324756-59-4P 324756-60-7P 324756-61-8P

10/ 071,483

324756-62-9P 324756-75-4P 324756-76-5P
324757-32-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. amines and amides as ligands for neuropeptide Y Y5 receptors useful in the treatment of obesity and other disorders)

RN 261715-55-3 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylsulfonyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-30-8 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-31-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-32-0 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-33-1 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/ 071,483

RN 324755-34-2 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-35-3 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylacetyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-36-4 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-4-piperidinyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-37-5 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-4-piperidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-38-6 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[[(phenylamino)carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-39-7 CAPLUS
CN 1-Piperidineacetamide, 4-(benzoylamino)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-46-6 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-47-7 CAPLUS

10/ 071,483

CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-48-8 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-49-9 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-50-2 CAPLUS
CN Benzenesulfonamide, N-[5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-, rel- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



RN 324755-58-0 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-59-1 CAPLUS
CN 1-Piperidineacetamide, 4-acetyl-4-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-60-4 CAPLUS

10/ 071,483

CN 1-Piperazineethanamine, 4-(2-methoxyphenyl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-80-8 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[(1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl)amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-81-9 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-(1,2,3,4-tetrahydro-2-naphthalenyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-82-0 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-84-2 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 324755-85-3 CAPLUS
CN 1-Piperidineacetamide, 4-acetyl-4-phenyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 324755-86-4 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 324755-87-5 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 324755-88-6 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl

RN 324755-89-7 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 324755-93-3 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-94-4 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-95-5 CAPLUS
CN 1-Piperidineacetamide, 4-acetyl-4-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-97-7 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324756-12-9 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-13-0 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-14-1 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-15-2 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-16-3 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-17-4 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-18-5 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-19-6 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-20-9 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-21-0 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-32-3 CAPLUS
CN 1-Piperidineacetamide, 4-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-33-4 CAPLUS
CN 1-Piperidineacetamide, 4-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-34-5 CAPLUS
CN 1-Piperidineacetamide, 4-[[(phenylamino)carbonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-35-6 CAPLUS
CN 1-Piperidineacetamide, 4-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-thienylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-36-7 CAPLUS
CN 1-Piperidineacetamide, 4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-40-3 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-thienylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-41-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-thienylmethyl)-2-naphthalenyl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-42-5 CAPLUS

10/ 071,483

CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-thienylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-43-6 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-methoxy-1-(3-thienylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-44-7 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-45-8 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-47-0 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-1-(1H-imidazol-4-ylmethyl)-6-methoxy-2-naphthalenyl]amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-48-1 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-49-2 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-51-6 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(1H-imidazol-4-ylmethyl)-6-methoxy-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-53-8 CAPLUS
CN Hexanamide, 2-amino-N-[1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]-6-[[(2-fluorophenyl)sulfonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-54-9 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-55-0 CAPLUS
CN Hexanamide, 2-amino-N-[6-fluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]-6-[(phenylsulfonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-56-1 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[6-fluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-57-2 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-58-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-59-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(2-propenyl)-2-naphthalenyl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-60-7 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 324756-61-8 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-(1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 324756-62-9 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-75-4 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 324756-18-5
CMF C29 H35 F N4 O4 S

Absolute stereochemistry.



10/ 071,483

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 324756-76-5 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 324756-19-6
CMF C29 H35 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 324757-32-6 CAPLUS
CN Benzenesulfonamide, N-[5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:2801 CAPLUS
DOCUMENT NUMBER: 134:176988
TITLE: Conformational restriction of the Tyr53 side-chain in the decapeptide HEL[52-61]: effects on binding to MHC-II I-Ak molecule and TCR recognition
AUTHOR(S): Casimir, J. R.; Iterbeke, K.; Van Den Nest, W.; Trescol-Biemont, M.-C.; Dumortier, H.; Muller, S.; Gerlier, D.; Rabourdin-Combe, C.; Tourwe, D.; Paris, J.
CORPORATE SOURCE: Laboratoire de Chimie Therapeutique, Universite Claude Bernard, Lyon, Fr.
SOURCE: Journal of Peptide Research (2000), 56(6), 398-408
CODEN: JPERFA; ISSN: 1397-002X
PUBLISHER: Munksgaard International Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:176988

AB A series of conformationally restricted analogs of the hen egg lysozyme (HEL) decapeptide 52-61 in which the conformationally flexible Tyr53 residue was replaced by several more constrained tyrosine and phenylalanine analogs was prepd. Among these tyrosine and phenylalanine analogs were 1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid (Htc), 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), 4-amino-1,2,4,5-tetrahydro-8-hydroxy-2-benzazepine-3-one (Hba), 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-one (Aba), 2-amino-6-hydroxytetralin-2-carboxylic acid (Hat) and 2-amino-5-hydroxyindan-2-carboxylic acid (Hai) in which the rotations around C.alpha.-C.beta. and C.beta.-C.gamma. were restricted because of cyclization of the side-chain to the backbone. Synthesis of Pht-Hba-Gly-OH using a modification of the Flynn and de Laszlo procedure is described. Analogs of .beta.-methyltyrosine (.beta.-MeTyr) in which the side-chains were biased to particular side-chain torsional angles because of substitution at the .beta.-hydrogens were also prepd. These analogs of HEL[52-61] peptide were tested for their ability to bind to the major histocompatibility complex class II I-Ak mol. and to be recognized in this context by two T-cell hybridomas, specific for the parent peptide HEL[52-61]. The data showed that the conformation and also the configuration of the Tyr53 residue influenced both the binding of the peptide to I-Ak and the recognition of the peptide/I-Ak complex by a T-cell receptor.

IT **288100-20-9P 288100-21-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antigenicity of)
RN 288100-20-9 CAPLUS

10/ 071,483

CN L-Arginine, L-.alpha.-aspartyl-(2S)-2-amino-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenecarbonylglycyl-L-isoleucyl-L-leucyl-L-glutaminyl-L-isoleucyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 288100-21-0 CAPLUS

CN L-Arginine, L-.alpha.-aspartyl-(2R)-2-amino-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenecarbonylglycyl-L-isoleucyl-L-leucyl-L-glutaminyl-L-isoleucyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:508629 CAPLUS
DOCUMENT NUMBER: 133:281663
TITLE: N-Acylated .alpha.-(3-pyridylmethyl)-.beta.-aminotetralin antagonists of the human neuropeptide Y Y5 receptor
AUTHOR(S): McNally, J. J.; Youngman, M. A.; Lovenberg, T. W.; Nepomuceno, D.; Wilson, S.; Dax, S. L.
CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(15), 1641-1643
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:281663
AB .alpha.-(3-Pyridylmethyl)-.beta.-aminotetralins were acylated with amino-piperidinyl and -pyrrolidinylacetic acids, and with

(aminomethyl)cyclohexanecarboxylic acid. Reaction with acyl chlorides, chloroformates, and isocyanates gave amides, carbamates, and ureas , which bound to the Y5 receptor with nanomolar affinity. Congeners contg. a terminal benzimidazolone group are functional Y5 antagonists.

IT **299203-75-1P 299203-76-2P 299203-77-3P**
299203-78-4P 299203-80-8P 299203-81-9P
299203-82-0P 299203-83-1P 299203-87-5P
299203-88-6P 299203-89-7P 299203-90-0P
299203-91-1P 299203-92-2P 299203-93-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of N-acylated .alpha.-(pyridylmethyl).beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 299203-75-1 CAPLUS
CN Benzamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-76-2 CAPLUS
CN Benzeneacetamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-77-3 CAPLUS
CN 1-Piperidineacetamide, 4-(benzoylamino)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-78-4 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylacetyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-80-8 CAPLUS
CN Carbamic acid, [[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-81-9 CAPLUS

10/ 071,483

CN Carbamic acid, [[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-82-0 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-4-piperidinyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-83-1 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-4-piperidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-87-5 CAPLUS
CN Cyclohexanecarboxamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-4-[[[(phenylamino)carbonyl]amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-88-6 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-4-[[(phenylamino)carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-89-7 CAPLUS

10/ 071,483

CN 1-Piperidineacetamide, 4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-90-0 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-91-1 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(2-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-92-2 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 299203-93-3 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(2-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/ 071,483

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:288664 CAPLUS
DOCUMENT NUMBER: 133:164302
TITLE: Synthesis and biological activities of constrained Tyr53 analogs of the immunogenic peptide Hel(52-61)
AUTHOR(S): Casimir, J. Richard; Trescol-Biemont, Marie-Claude; Tourwe, Dirk; Paris, Joelle; Ettouati, Laurent; Iterbeke, Koen; Van Den Nest, Wim; Gerlier, Denis; Rabourdin-Combe, Chantal
CORPORATE SOURCE: ISPB, Laboratoire de Chimie Therapeutique, Universite Claude Bernard, Lyon, F-69373, Fr.
SOURCE: Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (1999), Meeting Date 1998, 654-655. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Akademiai Kiado: Budapest, Hung.
CODEN: 68WKAY
DOCUMENT TYPE: Conference
LANGUAGE: English

AB A symposium report. The Tyr53 residue of HEL(52-61), 52Asp-Tyr-Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg61, an immunogenic peptide for MHC II I-Ak restricted T-cell is crucial for stimulation of 2A11 and 3A9 T cells. Amino acids which constrain the space available to the Tyr53 side chain have been incorporated into position 53 of HEL(52-61) and biol. activities of the analogs were detd.

IT **288100-19-6P 288100-20-9P 288100-21-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activities of constrained Tyr53 analogs of the immunogenic peptide Hel(52-61))

RN 288100-19-6 CAPLUS
CN L-Arginine, L-.alpha.-aspartyl-2-amino-1,2,3,4-tetrahydro-2-naphthalenecarbonylglycyl-L-isoleucyl-L-leucyl-L-glutaminyl-L-isoleucyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 288100-20-9 CAPLUS
CN L-Arginine, L-.alpha.-aspartyl-(2S)-2-amino-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenecarbonylglycyl-L-isoleucyl-L-leucyl-L-glutaminyl-L-isoleucyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

10/ 071,483

RN 288100-21-0 CAPLUS
CN L-Arginine, L-.alpha.-aspartyl-(2R)-2-amino-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenecarbonylglycyl-L-isoleucyl-L-leucyl-L-glutaminyl-L-isoleucyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:44072 CAPLUS
DOCUMENT NUMBER: 132:236840
TITLE: .alpha.-Substituted N-(Sulfonamido)alkyl-.beta.-aminotetralins: Potent and Selective Neuropeptide Y Y5 Receptor Antagonists
AUTHOR(S): Youngman, Mark A.; McNally, James J.; Lovenberg, Timothy W.; Reitz, Allen B.; Willard, Nicole M.; Nepomuceno, Diane H.; Wilson, Sandy J.; Crooke, Jeffrey J.; Rosenthal, Daniel; Vaidya, Anil H.; Dax, Scott L.
CORPORATE SOURCE: Drug Discovery The R. W. Johnson Pharmaceutical

10/ 071,483

Research Institute, Spring House, PA, 19477, USA
SOURCE: Journal of Medicinal Chemistry (2000), 43(3), 346-350
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Title compds. such as I (X = H2) were prepd. from .beta.-aminotetralins via the amides, e.g., I (X = O). The products were shown to be potent and selective antagonists of the human Y5 receptor and may be useful for treating feeding disorders and obesity.

IT **261715-50-8P 261715-51-9P 261715-52-0P**
261715-53-1P 261715-54-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 261715-50-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-51-9 CAPLUS
CN Cyclohexanecarboxamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[[(phenylsulfonyl)amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-52-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-53-1 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-54-2 CAPLUS
CN Cyclohexanecarboxamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]-4-[[(phenylsulfonyl)amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **247935-12-2P 247935-14-4P 247936-18-1P**
247936-30-7P 247936-57-8P 261715-55-3P
261715-59-7P 261715-61-1P 261715-62-2P
261715-63-3P 261715-64-4P 261715-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 247935-12-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-14-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-18-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-

10/ 071,483

tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-30-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-57-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-55-3 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylsulfonyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-59-7 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-61-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-62-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



RN 261715-63-3 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-64-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-65-5 CAPLUS
CN Benzenesulfonamide, N-[(5R)-5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **247935-08-6P 247936-86-3P 261715-78-0P 261715-80-4P 261715-81-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 247935-08-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 247936-86-3 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-78-0 CAPLUS

10/ 071,483

CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)-rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-77-9
CMF C29 H35 F N4 O4 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 261715-80-4 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-79-1
CMF C29 H35 F N4 O4 S

Relative stereochemistry.



10/ 071,483

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 261715-81-5 CAPLUS
CN Benzenesulfonamide, N-[(5R)-5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, trihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:783924 CAPLUS
DOCUMENT NUMBER: 132:18797
TITLE: Method for treating neurodegenerative disorders with tetrahydronaphthalenes, preparation thereof, pharmaceutical compositions, and screening and diagnostic methods
INVENTOR(S): Reitz, Allen B.; Demeter, David A.; Lee, Daniel H. S.; Wang, Hoau-Yan; Chen, Robert H.; Ross, Tina Morgan; Scott, Malcolm K.; Plata-Salaman, Carlos R.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962505	A2	19991209	WO 1999-US11702	19990527
WO 9962505	A3	20000406		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2333951	AA	19991209	CA 1999-2333951	19990527
AU 9945433	A1	19991220	AU 1999-45433	19990527
EP 1083889	A2	20010321	EP 1999-928342	19990527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2002013374	A1	20020131	US 1999-320885	19990527
US 6441049	B2	20020827		
JP 2002516853	T2	20020611	JP 2000-551761	19990527

PRIORITY APPLN. INFO.: US 1998-87577P P 19980601
US 1998-87577 P 19980601
WO 1999-US11702 W 19990527

OTHER SOURCE(S): MARPAT 132:18797

AB A method is provided for treating a neurodegenerative disorder, e.g. Alzheimer's disease, in a subject in need thereof which comprises administering to the subject an amt. of a tetrahydronaphthalene compd. (prepn. included) effective to inhibit the interaction of amyloid-.beta. with .alpha.7 nicotinic acetylcholine receptors.

IT **251974-95-5P 251974-96-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydronaphthalene deriv. prepn. for treatment of neurodegenerative disorders, pharmaceutical compns., and screening and diagnostic methods)

RN 251974-95-5 CAPLUS

CN 2-Naphthalenamine, N-(cyclohexylmethyl)-1,2,3,4-tetrahydro-5,8-dimethoxy-3-methyl-N-propyl-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 251974-96-6 CAPLUS

CN 1,4-Naphthalenediol, 6-[(cyclohexylmethyl)propylamino]-5,6,7,8-tetrahydro-7-methyl-, (6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/ 071,483



L3 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:708732 CAPLUS
DOCUMENT NUMBER: 131:310453
TITLE: Preparation of N-substituted aminotetralins as neuropeptide Y5 receptor ligands
INVENTOR(S): Dax, Scott L.; Lovenberg, Timothy Walter; McNally, James J.; Reitz, Allen B.; Youngman, Mark Andrew
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955667	A1	19991104	WO 1999-US7971	19990412
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9936400	A1	19991116	AU 1999-36400	19990412
US 6140354	A	20001031	US 1999-290651	19990412
BR 9910583	A	20010109	BR 1999-10583	19990412
EP 1076644	A1	20010221	EP 1999-918500	19990412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ZA 9902951	A	20001026	ZA 1999-2951	19990426
BG 104877	A	20010629	BG 2000-104877	20001023

PRIORITY APPLN. INFO.: US 1998-83415P P 19980429
US 1999-290651 A 19990412
WO 1999-US7971 W 19990412
OTHER SOURCE(S): MARPAT 131:310453
GI



I

AB Title compds. [I; R1 = H or 1 or 2 of halo, alkoxy, Ph, etc.; R4 = (CH2)0-3R2; R2 = H, halo, alkyl, Ph, etc.; R5,R6 = H or (halo)alkyl; R7 = NHZNHSO2R3; R3 = (cyclo)alkyl, Ph, heteroaryl, etc.; Z = (cycloalkylene-interrupted) alk(en)ylene, -alkynylene] were prepd. Thus, 6-methoxy-.beta.-tetralone was condensed with pyrrolidine and the product alkylated by PhCH2Br to give, after hydrolysis, I (R1 = 6-MeO, R4 = CH2Ph, R5 = H)(II; R6R7 = O) which was reductively aminated and the product amidated by trans-4-(2-naphthylsulfonamidomethyl)cyclohexanecarboxylic acid to give, after redn., (1.alpha.,2.alpha.,trans)-II (R6 = H, R7 = NHCH2Z1CH2NHSO2R3, R3 = 2-naphthyl, Z1 = 1,4-cyclohexylene). Data for biol. activity of I were given.

IT **247935-02-0P 247935-04-2P 247935-05-3P**
247935-07-5P 247935-08-6P 247935-09-7P
247935-10-0P 247935-11-1P 247935-12-2P
247935-14-4P 247935-16-6P 247935-17-7P
247935-18-8P 247935-19-9P 247935-26-8P
247935-27-9P 247935-28-0P 247935-29-1P
247935-30-4P 247935-31-5P 247935-32-6P
247935-33-7P 247935-34-8P 247935-35-9P
247935-36-0P 247935-37-1P 247935-38-2P
247935-39-3P 247935-40-6P 247935-41-7P
247935-42-8P 247935-43-9P 247935-44-0P
247935-45-1P 247935-46-2P 247935-47-3P
247935-48-4P 247935-49-5P 247935-50-8P
247935-51-9P 247935-52-0P 247935-53-1P
247935-54-2P 247935-55-3P 247935-56-4P
247935-57-5P 247935-58-6P 247935-59-7P
247935-60-0P 247935-61-1P 247935-62-2P
247935-63-3P 247935-64-4P 247935-65-5P
247935-66-6P 247935-67-7P 247935-68-8P
247935-69-9P 247935-70-2P 247935-71-3P
247935-72-4P 247935-73-5P 247935-74-6P
247935-75-7P 247935-76-8P 247935-77-9P
247935-78-0P 247935-79-1P 247935-80-4P
247935-81-5P 247935-82-6P 247935-83-7P
247935-84-8P 247935-85-9P 247935-86-0P
247935-87-1P 247935-88-2P 247935-89-3P
247935-90-6P 247935-91-7P 247935-92-8P
247935-93-9P 247935-94-0P 247935-95-1P
247935-96-2P 247935-97-3P 247935-98-4P
247935-99-5P 247936-00-1P 247936-01-2P
247936-02-3P 247936-03-4P 247936-04-5P
247936-05-6P 247936-06-7P 247936-07-8P
247936-08-9P 247936-09-0P 247936-10-3P
247936-11-4P 247936-12-5P 247936-13-6P
247936-14-7P 247936-15-8P 247936-16-9P
247936-17-0P 247936-18-1P 247936-19-2P
247936-20-5P 247936-21-6P 247936-22-7P
247936-23-8P 247936-24-9P 247936-25-0P
247936-26-1P 247936-27-2P 247936-28-3P
247936-29-4P 247936-30-7P 247936-31-8P
247936-32-9P 247936-33-0P 247936-34-1P
247936-35-2P 247936-36-3P 247936-38-5P

10/ 071,483

247936-39-6P 247936-40-9P 247936-41-0P
247936-42-1P 247936-43-2P 247936-44-3P
247936-45-4P 247936-46-5P 247936-47-6P
247936-48-7P 247936-49-8P 247936-50-1P
247936-51-2P 247936-52-3P 247936-53-4P
247936-54-5P 247936-55-6P 247936-56-7P
247936-57-8P 247936-58-9P 247936-59-0P
247936-91-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-substituted aminotetralins as neuropeptide Y5 receptor ligands)

RN 247935-02-0 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 247935-04-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



2 HCl

RN 247935-05-3 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-

10/ 071,483

, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 247935-07-5 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-phenyl-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 247935-06-4
CMF C35 H40 N2 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 247935-08-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



● HCl

RN 247935-09-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 247935-10-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-propyl-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HCl

RN 247935-11-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247935-12-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-14-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-16-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-17-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-18-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-phenyl-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-19-9 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-phenyl-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 247935-26-8 CAPLUS
CN 1-Naphthalenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-27-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-28-0 CAPLUS
CN Benzenesulfonamide, 3,4-dimethoxy-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-

10/ 071,483

(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-29-1 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-30-4 CAPLUS
CN Benzenesulfonamide, 4-(methylsulfonyl)-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-31-5 CAPLUS
CN Benzenesulfonamide, 3,5-dichloro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-32-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-33-7 CAPLUS
CN Benzenesulfonamide, 4-fluoro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-34-8 CAPLUS
CN 2-Thiophenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-35-9 CAPLUS
CN Benzenesulfonamide, 3-fluoro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-36-0 CAPLUS
CN Benzenesulfonamide, 2,4-dichloro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-37-1 CAPLUS
CN Benzenesulfonamide, 3-nitro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-38-2 CAPLUS
CN Benzenesulfonamide, 4-nitro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-39-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[6-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-nitro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-40-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-41-7 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-42-8 CAPLUS
CN Benzenesulfonamide, 2-(aminomethyl)-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-43-9 CAPLUS
CN Benzenesulfonamide, 2-bromo-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-44-0 CAPLUS
CN Benzenesulfonamide, 3-bromo-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-45-1 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-46-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-hydroxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-47-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-nitro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-48-4 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-49-5 CAPLUS
CN Benzenesulfonamide, 2-bromo-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) .(CA INDEX NAME)

Relative stereochemistry.



RN 247935-50-8 CAPLUS
CN Benzenesulfonamide, 2,3-dichloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-51-9 CAPLUS
CN Benzenesulfonamide, 2,4-dichloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-52-0 CAPLUS
CN Benzenesulfonamide, 2,6-dichloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-53-1 CAPLUS
CN Benzenesulfonamide, 3,4-dichloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-54-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-7-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-55-3 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-7-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-56-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(2-naphthalenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-57-5 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-(2-naphthalenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-58-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(3-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-59-7 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(3-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-60-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(2-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-61-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-62-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(4-nitrophenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-63-3 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(4-nitrophenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-64-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-65-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-nitro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-66-6 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[(2-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-67-7 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-68-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[1-[(3-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-69-9 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[[3-(trifluoromethyl)phenyl]methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-70-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-71-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1-[(3-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-72-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-73-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[[2-(trifluoromethyl)phenyl]methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-74-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[[3-(trifluoromethyl)phenyl]methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-75-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-methoxy-1-[[4-(trifluoromethyl)phenyl]methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-76-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[6-bromo-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-77-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[6-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-78-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-79-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[7-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-80-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[5-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-81-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[8-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-82-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[6,7-difluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-83-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6,7-dimethoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-84-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6,7-dihydroxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-85-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[1,2,3,4-tetrahydro-6-hydroxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-86-0 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-87-1 CAPLUS
CN Benzenesulfonamide, N-[4-[[[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]- (9CI) (CA INDEX NAME)



RN 247935-88-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-89-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-90-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-bromo-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-91-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-92-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-nitro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-93-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-5-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-94-0 CAPLUS
CN Benzenesulfonamide, 2,6-difluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-95-1 CAPLUS
CN Benzenesulfonamide, 2,4-difluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-96-2 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-97-3 CAPLUS
CN Benzenesulfonamide, 2-bromo-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-98-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-nitro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-99-5 CAPLUS
CN Benzenesulfonamide, 4-(aminomethyl)-2-chloro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-00-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-01-2 CAPLUS
CN Benzenesulfonamide, 2,4,6-trichloro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-02-3 CAPLUS
CN Benzenesulfonamide, 3-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-03-4 CAPLUS
CN Benzenesulfonamide, 4-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-04-5 CAPLUS
CN Benzenesulfonamide, 3,4-dimethoxy-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-05-6 CAPLUS
CN 1-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-06-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-naphthalenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-07-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-08-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-[(3-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-09-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-10-3 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-[(4-nitrophenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-11-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-naphthalenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-12-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-13-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-nitro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-14-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-[(2-methoxyphenyl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-15-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-[[4-(aminomethyl)phenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-16-9 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-17-0 CAPLUS
CN 2-Thiophenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-18-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-19-2 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[(1R,2S)-6,7-difluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-20-5 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-21-6 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-7-methoxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-22-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-(dimethylamino)-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-23-8 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-24-9 CAPLUS
CN Benzenesulfonamide, 2,6-difluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-25-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6,7-difluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2,4-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-26-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-7-fluoro-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-27-2 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-7-fluoro-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-28-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-amino-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-29-4 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(4-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-30-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-31-8 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(1H-imidazol-4-ylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-32-9 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1-(3-furanylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-33-0 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-thienylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-34-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1-(2-furanylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-35-2 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-methyl-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-36-3 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-propyl-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-38-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6,7-dihydroxy-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-39-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6,7-difluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-40-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-8-chloro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-41-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-[[4-(dimethylamino)phenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-42-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-43-2 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-44-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-45-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-46-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-(cyclopropylmethyl)-6-fluoro-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-47-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6,7-difluoro-1,2,3,4-tetrahydro-1-(1H-imidazol-4-ylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-48-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(1H-imidazol-4-ylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-49-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6,7-difluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-50-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-7-fluoro-1,2,3,4-tetrahydro-6-hydroxy-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-51-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-(cyclopropylmethyl)-7-fluoro-1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-52-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-(cyclopropylmethyl)-7-fluoro-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-53-4 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1-(cyclopropylmethyl)-6,7-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-54-5 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-[(1-methyl-1H-imidazol-4-yl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-55-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-[(1-methyl-1H-imidazol-4-yl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-56-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-[(1-methyl-1H-imidazol-4-yl)methyl]-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-57-8 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(2-propenyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-58-9 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-thienylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-59-0 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-1-(1H-imidazol-4-ylmethyl)-6-methoxy-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-91-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **247936-89-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-substituted aminotetralins as neuropeptide Y5 receptor ligands)
RN 247936-89-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

IT **247936-67-0P 247936-71-6P 247936-72-7P**
247936-73-8P 247936-77-2P 247936-78-3P
247936-79-4P 247936-83-0P 247936-86-3P
247936-87-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-substituted aminotetralins as neuropeptide Y5 receptor ligands)

RN 247936-67-0 CAPLUS

CN Cyclohexanecarboxamide, 4-[[(2-naphthalenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(phenylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-71-6 CAPLUS

CN Carbamic acid, [[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-72-7 CAPLUS
CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247936-73-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(2-naphthalenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-77-2 CAPLUS
CN Carbamic acid, [[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



RN 247936-78-3 CAPLUS
CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 247936-79-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(phenylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-83-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(2-naphthalenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-phenyl-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-86-3 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(2-propenyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-87-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-propyl-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:485957 CAPLUS
DOCUMENT NUMBER: 131:243049
TITLE: Synthesis and pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT
AUTHOR(S): Homan, Evert J.; Copinga, Swier; Unelius, Lena; Jackson, David M.; Wikstrom, Hakan V.; Grol, Cor J.
CORPORATE SOURCE: Department of Medicinal Chemistry, University Centre

for Pharmacy, University of Groningen, Groningen, NL-9713 AV, Neth.
SOURCE: Bioorganic & Medicinal Chemistry (1999), 7(7), 1263-1271
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The optically pure enantiomers of the potential atypical antipsychotic agents methoxybenzamidoethyl-N-propylaminotetralin I (R = H) (5-MeO-BPAT) and methoxy-N-dimethoxybenzamidoethyl-N-n-propylaminotetralin I (R = MeO) were synthesized and evaluated for their in vitro binding affinities at .alpha.1-, .alpha.2-, and .beta.-adrenergic, muscarinic, dopamine D1, D2A, and D3, and serotonin 5-HT1A and 5-HT2 receptors. In addn., their intrinsic efficacies at serotonin 5-HT1A receptors were established in vitro. Both enantiomers of I (R = H) had high affinities for dopamine D2A, D3, and serotonin 5-HT1A receptors, moderate affinities for .alpha.1-adrenergic and serotonin 5-HT2 receptors, and no affinity (Ki > 1000 nM) for the other receptor subtypes. Both enantiomers of I (R = MeO) had lower affinities for the dopamine D2A and the serotonin 5-HT1A receptor, compared to the enantiomers of I (R = H), and hence showed some selectivity for the dopamine D3 receptor. The interactions with the receptors were stereospecific, since the serotonin 5-HT1A receptor preferred the (S)-enantiomers of I while the dopamine D2A and D3 receptors preferred the (R)-enantiomers of I. The intrinsic efficacies at the serotonin 5-HT1A receptor were established by measuring their ability to inhibit VIP-induced cAMP prodn. in GH4ZD10 cells expressing serotonin 5-HT1A receptors. Both enantiomers of I (R = H) behaved as full serotonin 5-HT1A receptor agonists in this assay, while both enantiomers of I (R = MeO) behaved as weak partial agonists. The potential antipsychotic properties of (S)- and (R)-I (R = H) were evaluated by establishing their ability to inhibit d-amphetamine-induced locomotor activity in rats, while their propensity to induce extrapyramidal side-effects (EPS) in man was evaluated by detg. their ability to induce catalepsy in rats. Whereas (R)-I (R = H) was capable of blocking d-amphetamine-induced locomotor activity, indicative of dopamine D2 receptor antagonism, (S)-I (R = H) even enhanced the effect of d-amphetamine, suggesting that this compd. has dopamine D2 receptor-stimulating properties. Since both enantiomers of I (R = H) also were devoid of cataleptogenic activity, they are interesting candidates for further exploring the dopamine D2/serotonin 5-HT1A hypothesis of atypical antipsychotic drug action.

IT **244239-73-4P 244239-74-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of propylbenzoylaminotetralins and their enantiomers as potential antipsychotic agents and their binding to adrenergic, dopamine, and serotonin receptors)

RN 244239-73-4 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-[(2S)-1,2,3,4-tetrahydro-5-methoxy-2-

10/ 071,483

naphthalenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

RN 244239-74-5 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-[(2R)-1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:414226 CAPLUS
DOCUMENT NUMBER: 131:170152
TITLE: Structural analogs of 5-OMe-BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors
AUTHOR(S): Homan, Evert J.; Kroodsma, Esther; Copinga, Swier; Unelius, Lena; Mohell, Nina; Wikstrom, Hakan V.; Grol, Cor J.
CORPORATE SOURCE: Department of Medicinal Chemistry, University Centre for Pharmacy, University of Groningen, Groningen, NL-9713, Neth.
SOURCE: Bioorganic & Medicinal Chemistry (1999), 7(6), 1111-1121
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

10/ 071,483

GI



I

AB Several structural analogs of 5-OMe-BPAT (I), a representative of a series of 2-aminotetralin-derived benzamides with potential atypical antipsychotic properties, were synthesized and evaluated for their ability to bind to dopamine D2A, D3, and serotonin 5-HT1A receptors in vitro. The structure-affinity relationships revealed that the arom. ring of the benzamide moiety of I contributes to the high affinities for all three receptor subtypes. Furthermore, I may interact with the dopamine D2 and D3 receptors through hydrogen bond formation with its carbonyl group. Investigation of the role of the amide hydrogen atom by amide N-alkylation was not conclusive, since conformational aspects may be responsible for the decreased dopaminergic affinities of the N'-alkylated analogs of I. The effects of amide modifications on serotonin 5-HT1A receptor affinity were less pronounced, suggesting that the benzamidoethyl side-chain of I as a whole enhances the affinity for this receptor subtype, probably through hydrophobic interactions with an accessory binding site. The structural requirements for the substituents at the basic nitrogen atom supported the hypothesis that the 2-aminotetralin moieties of the 2-aminotetralin-derived substituted benzamides may share the same binding sites as the 2-(di-n-propylamino)tetralins.

IT **220772-90-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
([(benzamidoethyl)amino]tetralins and their affinity for dopamine D2, D3, and serotonin 5-HT1A receptors)

RN 220772-90-7 CAPLUS

CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **238411-33-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
([(benzamidoethyl)amino]tetralins and their affinity for dopamine D2, D3, and serotonin 5-HT1A receptors)

RN 238411-33-1 CAPLUS

CN 1,2-Ethanediamine, N-(phenylmethyl)-N-(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

10/ 071,483



IT **238411-49-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
([(benzamidoethyl)amino]tetralins and their affinity for dopamine D2, D3, and serotonin 5-HT1A receptors)
RN 238411-49-9 CAPLUS
CN 1,2-Ethanediamine, N-(phenylmethyl)-N-(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 238411-33-1
CMF C20 H26 N2 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:1963 CAPLUS
DOCUMENT NUMBER: 130:191424
TITLE: 2-Aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents
AUTHOR(S): Homan, Evert J.; Copinga, Swier; Elfstrom, Lotta; Van Der Veen, Trees; Hallema, Jan-Pieter; Mohell, Nina; Unelius, Lena; Johansson, Rolf; Wikstrom, Hakan V.; Grol, Cor J.
CORPORATE SOURCE: Department of Medicinal Chemistry, University Centre for Pharmacy, University of Groningen, Groningen,

10/ 071,483

NL-9713 AV, Neth.
SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(11), 2111-2126
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new chem. class of potential atypical antipsychotic agents, based on the pharmacol. concept of mixed dopamine D2 receptor antagonism and serotonin 5-HT1A receptor agonism, was designed by combining the structural features of the 2-(N,N-di-n-propylamino)tetralins (DPATs) and the 2-pyrrolidinylmethyl-derived substituted benzamides in a structural hybrid. Thus, a series of 35 differently substituted 2-aminotetralin-derived substituted benzamides was synthesized and the compds. were evaluated for their ability to compete for [3H]-raclopride binding to cloned human dopamine D2A and D3 receptors, and for [3H]-8-OH-DPAT binding to rat serotonin 5-HT1A receptors in vitro. The lead compd. of the series, 5-methoxy-2-[N-(2-benzamidoethyl)-N-n-propylamino]tetralin, displayed high affinities for the dopamine D2A receptor (Ki = 3.2 nM), the dopamine D3 receptor (Ki = 0.58 nM) as well as the serotonin 5-HT1A receptor (Ki = 0.82 nM). The structure-affinity relationships of the series suggest that the 2-aminotetralin moieties of the compds. occupy the same binding sites as the DPATs in all three receptor subtypes. The benzamidoethyl side chain enhances the affinities of the compds. for all three receptor subtypes, presumably by occupying an accessory binding site. For the dopamine D2 and D3 receptors, this accessory binding site may be identical to the binding site of the 2-pyrrolidinylmethyl-derived substituted benzamides.

IT **101403-17-2P 116618-94-1P 220772-90-7P**
220772-91-8P 220772-93-0P 220772-94-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of 2-aminotetralin-derived substituted benzamides with mixed dopamine D2 and D3 and serotonin 5-HT1A receptor binding properties as novel atypical antipsychotic agents)

RN 101403-17-2 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 116618-94-1 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 220772-90-7 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 220772-91-8 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 220772-93-0 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220772-92-9
CMF C16 H26 N2 O

10/ 071,483



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 220772-94-1 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:806651 CAPLUS
DOCUMENT NUMBER: 130:52426
TITLE: Preparation of N-[(naphthyldioxanyl)propyl]glycinates and analogs as neuroprotectants
INVENTOR(S): Dargazanli, Gihad; Lardenois, Patrick; Frost, Jonathan; George, Pascal
PATENT ASSIGNEE(S): Synthelabo S. A., Fr.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855474	A1	19981210	WO 1998-FR1113	19980603

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

FR 2764287	A1	19981211	FR 1997-6944	19970605
FR 2764287	B1	19990716		
FR 2764288	A1	19981211	FR 1997-6945	19970605
FR 2764288	B1	19990716		
FR 2764289	A1	19981211	FR 1997-6946	19970605
FR 2764289	B1	19990716		
FR 2764291	A1	19981211	FR 1997-6947	19970605
FR 2764291	B1	19990716		
AU 9880251	A1	19981221	AU 1998-80251	19980603
EP 986552	A1	20000322	EP 1998-928419	19980603

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

EE 9900560	A	20000615	EE 1999-560	19980603
BR 9810742	A	20000912	BR 1998-10742	19980603
JP 2002502412	T2	20020122	JP 1999-501723	19980603
ZA 9804854	A	19990104	ZA 1998-4854	19980604
NO 9905966	A	20000204	NO 1999-5966	19991203

PRIORITY APPLN. INFO.:

FR 1997-6944	A	19970605
FR 1997-6945	A	19970605
FR 1997-6946	A	19970605
FR 1997-6947	A	19970605
WO 1998-FR1113	W	19980603

OTHER SOURCE(S): MARPAT 130:52426

AB Title compds., e.g., R1OZ1Z2(CH2)3NR2CH2COR3 [R1,R2 = H, (cyclo)alkyl, phenylalkyl, etc.; R3 = OH, alkoxy, (di)(alkyl)amino, etc.; Z1 = 6,1-naphthylene, Z2 = 1,3-dioxane-5,2-diyl throughout] were prepd. Thus, R1OZ1Z2(CH2)3NR2R (R1 = cyclopropyl)(I; R = H, R2 = Ac) was reduced and the product condensed with cyclopropylmethylamine/ClCH2COCl to give I (R = CH2COR3, R2 = Et, R3 = cyclopropylmethylamino). Data for biol. activity of I were given.

IT **217183-28-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-[(naphthyldioxanyl)propyl]glycinates and analogs as neuroprotectants)

RN 217183-28-3 CAPLUS

CN Acetamide, 2-[[3-[5-(6-methoxy-1-naphthalenyl)-1,3-dioxan-2-yl]propyl](1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:87705 CAPLUS
DOCUMENT NUMBER: 128:167711
TITLE: Preparation of alpha-amino acid amides useful for the treatment of neurological diseases
INVENTOR(S): Chiesi, Paolo; Ventura, Paolo; Delcanale, Maurizio; De Fanti, Renato; Armani, Elisabetta; Villetti, Gino; Pietra, Claudio
PATENT ASSIGNEE(S): Chiesi Farmaceutici S.P.A., Italy; Chiesi, Paolo; Ventura, Paolo; Delcanale, Maurizio; De Fanti, Renato; Armani, Elisabetta; Villetti, Gino; Pietra, Claudio
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803472	A1	19980129	WO 1997-EP3773	19970715
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9736952	A1	19980210	AU 1997-36952	19970715
AU 729176	B2	20010125		
CN 1225625	A	19990811	CN 1997-196604	19970715
EP 951465	A1	19991027	EP 1997-933680	19970715
EP 951465	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 333869	A	20000526	NZ 1997-333869	19970715
JP 2001506577	T2	20010522	JP 1998-505424	19970715
RU 2174511	C2	20011010	RU 1999-103681	19970715
IL 128020	A1	20020421	IL 1997-128020	19970715
AT 237584	E	20030515	AT 1997-933680	19970715
NO 9900300	A	19990122	NO 1999-300	19990122
US 6114391	A	20000905	US 1999-147553	19990218

PRIORITY APPLN. INFO.: IT 1996-MI1544 A 19960723
WO 1997-EP3773 W 19970715
OTHER SOURCE(S): MARPAT 128:167711

AB Serinamide, glycinamide, alaninamide and phenylalaninamide derivs. of formula R'RNCHR1CONHR2 (R'= H, alkyl, Ph, phenylalkyl; R = straight or branched alkyl, cycloalkylalkyl, arylalkyl or phenylalkyl optionally substituted at the ring with alkyl, halogen, or haloalkyl, fused or non-fused aryl optionally substituted with alkyl, alkoxy, halogen, or haloalkyl; R1 = optionally acylated C1-4 hydroxyalkyl or phenylalkyl, H, Me; R2 = hydrogen, alkyl, Ph, phenylalkyl), useful for the treatment of neurol. diseases, were prepd. Thus, reductive amination of L-serine Me ester hydrochloride and 3-phenylpropionaldehyde according to conventional methods using hydrogen in the presence of 10% Pd/C as a reducing agent and conversion to the hydrochloride salt by dissoln. in Et ether and acidification with methanol hydrochloric acid gave Ph(CH2)3-L-Ser-OMe.HCl. The latter compd. was dissolved in water and alkalinized with 10% aq. potassium carbonate to pH = 8 to give the free base which was extd. with methylene chloride and evapd. to dryness under vacuum, dissolved in

methanol, ammonia was bubbled through the soln., and cooled to -5.degree. to a ~15M concn. The hermetically sealed system was reacted for 5 days at room temp., evapd. to dryness under vacuum, and the product recovered as the HCl salt by dissoln. in ethanol, acidification with ether HCl, and pptn. with Et ether to give (S)-Ph(CH2)3NHCH(CH2OH)CONH2.HCl. The examd. compds. showed a potency of anticonvulsant activity better than that of milacemide and/or sodium valproate in the mouse maximal electroshock (MES) test. The ED50 values were comprised between 1.2 and 0.5 mmol/kg with a potency ratio ranging from 4.5 to 35 with respect to milacemide and from 1 to 6.7 with respect to sodium valproate. Also, all the tested compds. were about 3-4 times more potent than 3-hydroxy-2-(4-(3-phenylpropyloxy)benzylamino)propanamide methanesulfonate (FCE28245).

IT **202914-09-8P**, CHF 2818
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of alpha-amino acid amides useful for the treatment of neurol. diseases)

RN 202914-09-8 CAPLUS

CN Propanamide, 3-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, [2(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **202914-10-1P**, CHF 2983 **202914-11-2P**, CHF 2982.01
202914-27-0P, CHF 2991.01 **202914-42-9P**, CHF 2983.01
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of alpha-amino acid amides useful for the treatment of neurol. diseases)

RN 202914-10-1 CAPLUS

CN Propanamide, 3-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 202914-11-2 CAPLUS

CN Propanamide, 3-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, monohydrochloride, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 071,483



● HCl

RN 202914-27-0 CAPLUS
CN Propanamide, 3-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 202914-42-9 CAPLUS
CN Propanamide, 3-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:640655 CAPLUS
DOCUMENT NUMBER: 127:307398
TITLE: New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivatives useful as 5-HT antagonists
INVENTOR(S): Berg, Stefan; Florvall, Lennart; Ross, Svante; Thorberg, Seth-Olov

10/ 071,483

PATENT ASSIGNEE(S): Astra AB, Swed.; Berg, Stefan; Florvall, Lennart; Ross, Svante; Thorberg, Seth-Olov
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734883	A1	19970925	WO 1997-SE469	19970320
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9702056	A	19970922	ZA 1997-2056	19970310
CA 2247940	AA	19970925	CA 1997-2247940	19970320
AU 9721865	A1	19971010	AU 1997-21865	19970320
AU 709856	B2	19990909		
EP 888319	A1	19990107	EP 1997-914727	19970320
EP 888319	B1	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1219170	A	19990609	CN 1997-194726	19970320
CN 1073101	B	20011017		
BR 9708093	A	19990727	BR 1997-8093	19970320
NZ 331613	A	20000327	NZ 1997-331613	19970320
JP 2000506883	T2	20000606	JP 1997-533410	19970320
SK 282359	B6	20020107	SK 1998-1188	19970320
AT 231847	E	20030215	AT 1997-914727	19970320
US 6124283	A	20000926	US 1997-836004	19970425
NO 9804385	A	19981123	NO 1998-4385	19980921
US 6410530	B1	20020625	US 2000-653427	20000831

PRIORITY APPLN. INFO.: SE 1996-1110 A 19960322
WO 1997-SE469 W 19970320
US 1997-836004 A3 19970425
OTHER SOURCE(S): MARPAT 127:307398
GI



I



II

AB New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivs. I [X = N or CH; Y = NR2CH2, CH2NR2, NR2CO, CONR2, or NR2SO2; R1 = H, C1-6 alkyl, or C3-6 cycloalkyl; R2 = H or C1-6 alkyl; R3 = C1-6 alkyl, C3-6 cycloalkyl, or (CH2)n-aryl where aryl = Ph or heteroarom. ring contg. 1 or 2 N/O/S atoms and which may be mono- or di-substituted; n = 0-4], as enantiomers, racemates, free bases, or pharmaceutically acceptable salts or hydrates, are disclosed. Also disclosed are pharmaceutical formulations contg. I, use of I in the treatment of disorders mediated by 5-hydroxytryptamine (5-HT), and processes and intermediates for the prepn. of I. The compds. are primarily selective antagonists of the 5-HT1D receptor (no data). A variety of preferred compds., mostly (R)-isomers, are specifically claimed. Synthetic examples (138) include prepn. of both I and their intermediates. For instance, (R)-8-methoxy-2-amino-1,2,3,4-tetrahydronaphthalene-HCl was converted in 8 steps to (R)-2-amino-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene, which was condensed with 4-morpholinobenzoic acid using 1,1'-carbonyldiimidazole in DMF to give title compd. II.

IT **197445-40-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperidinyl- and piperazinyl-substituted tetrahydronaphthalenes as 5-HT1D antagonists)

RN 197445-40-2 CAPLUS

CN Cyclohexanecarboxamide, N-[1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L3 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:382751 CAPLUS
DOCUMENT NUMBER: 125:58082
TITLE: Preparation of N-acyltetralinamines and analogs as cholesterol biosynthesis inhibitors
INVENTOR(S): Woitun, Eberhard; Maier, Roland; Mueller, Peter; Hurnaus, Rudolf; Mark, Michael; Eisele, Bernhard; Budzinski, Ralph-Michael; Hallermayer, Gerhard
PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4438029	A1	19960502	DE 1994-4438029	19941025

PRIORITY APPLN. INFO.: DE 1994-4438029 19941025
OTHER SOURCE(S): MARPAT 125:58082
GI



AB Title compds. [I; R1 = H, halo, alkyl, alkoxy, etc.; R2 = H or alkyl; R3 = alk(en)yl, Ph, cyclohexyl, etc.; R4 = (phenyl)alk(en)yl, Ph, cyclohexyl(alkyl), etc.; R5,R6 = H, alkyl, phenyl(alkyl); NR4R5 = heterocyclyl; m = 0-2; n = 2-4] were prepd. Thus, 6-methoxy-2-tetralone was reductively aminated by MeNH and the product N-acylated by BuCH2COCl to give, after ether cleavage and reetherification with Et2NCH2CH2Cl, title compd. II which had IC50 of 10-6M against cholesterol biosynthesis in human hepatoma cells in vitro.

IT **178057-85-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/ 071,483

(prepn. of N-acyltetralinamines and analogs as cholesterol biosynthesis inhibitors)

RN 178057-85-7 CAPLUS

CN Cyclohexanecarboxamide, N-[6-[2-(diethylamino)ethoxy]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **178058-10-1P 178058-32-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-acyltetralinamines and analogs as cholesterol biosynthesis inhibitors)

RN 178058-10-1 CAPLUS

CN Cyclohexanecarboxamide, N-methyl-N-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 178058-32-7 CAPLUS

CN Cyclohexanecarboxamide, N-methyl-N-(1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:138926 CAPLUS

DOCUMENT NUMBER: 118:138926

TITLE: Thin-layer chromatography of the positional isomers of some 1,2,3,4-tetrahydro-2-naphthol and 3-amino-1,2,3,4-tetrahydro-2-naphthol derivatives

AUTHOR(S): Drandarov, Konstantin; Hais, Ivo M.

CORPORATE SOURCE: Dep. Biochem. Sci., Fac. Pharm, Charles Univ., Heyrovskeho 1203, Hradec Kralove, 501 65, Czech.

SOURCE: Journal of Chromatography (1993), 628(1), 103-9
CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The sepn. of 29 isomer pairs, namely three pairs of 5- and/or 8-substituted 1,2,3,4-tetrahydronaphthols, one pair of naphthalene derivs. (naphthalene-1,7-diol and naphthalene-1,6-diol) and 25 pairs of

10/ 071,483

N-substituted 3-amino-1,2,3,4-tetrahydro-2-naphthols {including their lactone derivs., tetrahydro-4H-naphth[2,3-b][1,4]oxazin-2-ones} in TLC systems on silica or alumina was studied. The possibility of two-point contact with the adsorbent in the case of more strongly retained isomers and their edgewise orientation against its surface is discussed. Attention is also paid to the influence of substituents in position 3 of the 1,2,3,4-tetrahydro-2-naphthol ring system on the retention sequence of the resp. isomers.

IT **146511-59-3 146511-60-6 146511-65-1**
146511-66-2 146511-85-5 146511-86-6
RL: ANST (Analytical study); PROC (Process)
(sepn. of, from positional isomers by thin-layer chromatog.)

RN 146511-59-3 CAPLUS
CN Acetamide, N-(2-amino-2-oxoethyl)-N-(1,2,3,4-tetrahydro-3,8-dihydroxy-5-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 146511-60-6 CAPLUS
CN Acetamide, N-(2-amino-2-oxoethyl)-N-(1,2,3,4-tetrahydro-3,5-dihydroxy-8-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 146511-65-1 CAPLUS
CN Acetamide, N-[8-(acetyloxy)-1,2,3,4-tetrahydro-3-hydroxy-8-methoxy-2-naphthalenyl]-N-(2-amino-2-oxoethyl)- (9CI) (CA INDEX NAME)



RN 146511-66-2 CAPLUS
CN Acetamide, N-[5-(acetyloxy)-1,2,3,4-tetrahydro-3-hydroxy-8-methoxy-2-naphthalenyl]-N-(2-amino-2-oxoethyl)- (9CI) (CA INDEX NAME)

10/ 071,483



RN 146511-85-5 CAPLUS
CN Carbamic acid, (2-amino-2-oxoethyl)(1,2,3,4-tetrahydro-3,8-dihydroxy-5-methoxy-2-naphthalenyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 146511-86-6 CAPLUS
CN Carbamic acid, (2-amino-2-oxoethyl)(1,2,3,4-tetrahydro-3,5-dihydroxy-8-methoxy-2-naphthalenyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:492956 CAPLUS
DOCUMENT NUMBER: 115:92956
TITLE: Preparation of 2-[N-(.alpha.-aminoacyl or dipeptidyl)]amino-6,7-dimethoxytetralin derivatives as antihypertensives
INVENTOR(S): Marzi, Mauro; Tinti, Maria Ornella; Pacifici, Licia; Franceschelli, Carla; Castorina, Massimo
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

10/ 071,483

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 412061	A2	19910206	EP 1990-830347	19900726
EP 412061	A3	19910814		
EP 412061	B1	19941005		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, LI, LU, NL, SE				
ES 2062492	T3	19941216	ES 1990-830347	19900726
JP 03178955	A2	19910802	JP 1990-203746	19900730
US 5053424	A	19911001	US 1990-559052	19900730

PRIORITY APPLN. INFO.: IT 1989-48254 19890731
OTHER SOURCE(S): MARPAT 115:92956
GI



I

AB The title compds. (I; R = H, Et; A = aminoacyl, dipeptidyl) are prepd. Thus, to a soln. of 2.07 mmol 2-amino-6,7-dimethoxytetralin in CH2Cl2 were added 2.07 mmol DCC and Boc-Gly-OH (Boc = Me3CO2C) and the soln. was stirred 2 h to give 86% I (R = H, A = Boc-Gly). This was treated with 2 mL HCO2H for 30 min after aq. work-up, neutralization, and extn., 62% I (R = H, A = H-Gly). I.HCl (R = H, A = H-L-Tyr-L-Ala) at 2 mg i.p. lowered the blood pressure of SHR hypertensive rats by 40 mmHg at the 1st h and 29 mmHg at the 4th h after the drug administration. A total of 10 I were prepd. and tested for antihypertensive activity.

IT **135528-18-6P 135528-19-7P 135528-20-0P**
135528-21-1P 135528-27-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antihypertensive)

RN 135528-18-6 CAPLUS
CN Acetamide, 2-amino-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135528-19-7 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)



● HCl

RN 135528-20-0 CAPLUS
CN 1H-Indole-3-propanamide, .alpha.-amino-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)



● HCl

RN 135528-21-1 CAPLUS
CN Benzenepropanamide, .alpha.-amino-4-hydroxy-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)



● HCl

RN 135528-27-7 CAPLUS
CN Acetamide, 2-amino-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:57322 CAPLUS

10/ 071,483

DOCUMENT NUMBER: 110:57322
TITLE: Preparation of 2-aminotetralin derivatives as drugs
INVENTOR(S): Schohe, Rudolf; Glaser, Thomas; Traber, Joerg; Allen, George S.
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 82 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3718317	A1	19880616	DE 1987-3718317	19870601
NO 8704939	A	19880613	NO 1987-4939	19871126
NO 166639	B	19910513		
NO 166639	C	19910821		
EP 270947	A2	19880615	EP 1987-117549	19871127
EP 270947	A3	19881228		
EP 270947	B1	19930519		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 89546	E	19930615	AT 1987-117549	19871127.
ES 2054649	T3	19940816	ES 1987-117549	19871127
JP 01153662	A2	19890615	JP 1987-304711	19871203
FI 8705395	A	19880611	FI 1987-5395	19871208
US 4880802	A	19891114	US 1987-130373	19871208
DD 281376	A5	19900808	DD 1987-310089	19871208
CA 1332834	A1	19941101	CA 1987-553731	19871208
DK 8706470	A	19880611	DK 1987-6470	19871209
ZA 8709254	A	19880831	ZA 1987-9254	19871209
HU 46654	A2	19881128	HU 1987-5542	19871209
AU 8782417	A1	19880616	AU 1987-82417	19871210
AU 606904	B2	19910221		
CN 87107539	A	19880713	CN 1987-107539	19871210
US 5026857	A	19910625	US 1989-378733	19890712
US 5153225	A	19921006	US 1991-682823	19910409
US 4880802	B1	19940125	US 1991-90002346	19910510
US 5298513	A	19940329	US 1992-891485	19920529
US 5463105	A	19951031	US 1993-131267	19931001

PRIORITY APPLN. INFO.:
DE 1986-3642192 19861210
DE 1987-3718317 19870601
EP 1987-117549 19871127
US 1987-130373 19871208
US 1989-378733 19890712
US 1991-682823 19910409
US 1992-891485 19920529

OTHER SOURCE(S): CASREACT 110:57322; MARPAT 110:57322
GI



I

AB Title compds. I [R1 = H, alkyl; R2 = H, acyl, alkyl, R3 = quinuclidinyl, (substituted) alkyl, alkenyl, alkynyl, or benzyl, heterocyclyl] are prepd. for treating central nervous system, cardiovascular, and intestinal

disorders in humans and animals. Reductive amination of 3.0 mmol 8-methoxy-2-tetralone with 9.0 mmol 4-(ethoxycarbonylaminomethyl)piperidine and NaBH3CN in MeOH gave 43% I [R1 = Me; NR2R3 = 4-(ethoxycarbonylaminomethyl)piperidino] (II). In tests measuring contraction of arteria basilaris in dogs II.2HCl showed a serotonin antagonistic effect.

IT **116618-93-0P 116618-94-1P 116619-08-0P 116619-22-8P 116619-23-9P 117347-07-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as central nervous system, cardiovascular and gastrointestinal agent)

RN 116618-93-0 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 116618-94-1 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 116619-08-0 CAPLUS
CN 2,6-Piperidinedione, 4,4-dimethyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 116619-22-8 CAPLUS
CN 2,6-Piperidinedione, 3-phenyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)

10/ 071,483



RN 116619-23-9 CAPLUS
CN 2,6-Piperidinedione, 3-phenyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 117347-07-6 CAPLUS
CN 2,6-Piperidinedione, 4,4-dimethyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1988:549105 CAPLUS
DOCUMENT NUMBER: 109:149105
TITLE: Preparation of substituted 2-aminotetralins as neurotransmitter agonists and antagonists
INVENTOR(S): Schohe, Rudolf; Glaser, Thomas; Traber, Joerg; Allen, George S.
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 229 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

10/ 071,483

EP 270947	A2	19880615	EP 1987-117549	19871127
EP 270947	A3	19881228		
EP 270947	B1	19930519		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
DE 3718317	A1	19880616	DE 1987-3718317	19870601
AT 89546	E	19930615	AT 1987-117549	19871127

PRIORITY APPLN. INFO.: DE 1986-3642192 19861210
DE 1987-3718317 19870601
EP 1987-117549 19871127

OTHER SOURCE(S): MARPAT 109:149105

GI



I Q

AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, acyl; R3 = quinuclidinyl, Q, (CH2)aR4, CH2CH:CH(CH2)bR4, CH2C.tplbond.C(CH2)bR4, CH2C6H4(CH2)bR4; NR2R3 = Q; R4 = cyano, Q, indolyl, etc.; X = O, S, NR5; R5 = H, cycloalkyl, aryl, (un)substituted alkyl, etc.; a = 1-10; b = 0-4; c = 0-2; d = 2, 3] were prepd. 8-Methoxy-2-propylamino-1,2,3,4-tetrahydronaphthalene and ClCH2CN were stirred overnight at 60.degree. in MeCOEt contg. K2CO3 and NaI to give I (R1 = Me, R2 = Pr, R3 = CH2CN) which was added to LiAlH4 in Et2O previously stirred with H2SO4 and oleum and the mixt. refluxed 2 h to give I (R1 = Me, R2 = Pr, R3 = CH2CH2NH2). The latter was stirred 15 h with 4-MeC6H4SO2Cl in CH2Cl2 to give I.HCl (R1 = Me, R2 = Pr, R3 = CH2CH2NHSO2C6H4Me-4) which had Ki = 1 nmol/L for 5HT1 receptor binding and had serotonin antagonist activity in vitro.

IT **116618-67-8P 116618-93-0P 116618-94-1P**
116619-08-0P 116619-22-8P 116619-23-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as neurotransmitter agonist or antagonist)

RN 116618-67-8 CAPLUS

CN 1,2-Ethanediamine, N-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116618-93-0 CAPLUS

CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 116618-94-1 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 116619-08-0 CAPLUS
CN 2,6-Piperidinedione, 4,4-dimethyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 116619-22-8 CAPLUS
CN 2,6-Piperidinedione, 3-phenyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 116619-23-9 CAPLUS
CN 2,6-Piperidinedione, 3-phenyl-1-[2-[propyl(1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/ 071,483



● HCl

L3 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:207119 CAPLUS
DOCUMENT NUMBER: 104:207119
TITLE: Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents
AUTHOR(S): Seiler, Max P.; Stoll, Andre P.; Closse, Annemarie; Frick, Willy; Jaton, Annelise; Vigouret, Jean Marie
CORPORATE SOURCE: SANDOZ Ltd., Basel, CH-4002, Switz.
SOURCE: Journal of Medicinal Chemistry (1986), 29(6), 912-17
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 104:207119
GI



I

AB 5-Hydroxy-2-aminotetralin derivs. in which one N-alkyl substituent carries a functional group, e.g. I [R = (CH2)3CN, (CH2)4NH2, (CH2)3OH, CH2CH2Ph], were prepd. and their dopaminergic activities compared with those of 5-hydroxy-2-(dipropylamino)tetralin (5-OH-DPAT) and known ergolines. Several members of the series demonstrated high affinities in dopamine (DA) receptor binding and DA agonist properties in the rotational behavior model in the range of known potent ergolines. The results suggest that the accessory binding site for the larger N-alkyl substituent of the 5-hydroxy-2-aminotetraline can accommodate various neutral and bulky functionalities and is probably identical with the site(s) to which the 8-substituents of the ergolines bind.

IT **101403-17-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and demethylation of)
RN 101403-17-2 CAPLUS
CN 1,2-Ethanediamine, N-propyl-N-(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

10/ 071,483



L3 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:55638 CAPLUS
DOCUMENT NUMBER: 102:55638
TITLE: Pharmacological study of 2-aminotetralin derivatives
AUTHOR(S): Staneva, D.; Rainova, L.; Chakurova, L.; Georgieva, A.; Ivanov, D.
CORPORATE SOURCE: Vissh Med. Inst., Sofia, Bulg.
SOURCE: Farmatsiya (Sofia, Bulgaria) (1984), 34(3), 15-19
CODEN: FMTYA2; ISSN: 0428-0296
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
GI



I



II

AB Several series of the title compds., including I (NR2 = NHCHMe2, NH-iso-Bu, NH-tert-Bu, NMe2, NEt2, or N-contg. heterocycle group) and II (AR = substituted Ph) were tested in mice for biol. activity. A variety of activities were obsd., including hypotensive, hypertensive, antiarrhythmic, sedative, antihistaminic, and analgesic activities. Mol. structure-biol. activity relations are discussed.

IT **92311-92-7 94497-25-3 94497-26-4D**, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. activity of, structure in relation to)

RN 92311-92-7 CAPLUS
CN 1-Piperidineacetamide, N-(1,2,3,4-tetrahydro-3-hydroxy-5,8-dimethoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/ 071,483



RN 94497-25-3 CAPLUS
CN 1-Piperazineacetamide, 4-(2-hydroxyethyl)-N-(1,2,3,4-tetrahydro-3-hydroxy-5,8-dimethoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 94497-26-4 CAPLUS
CN Acetamide, 2-amino-N-(1,2,3,4-tetrahydro-3-hydroxy-5,8-dimethoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:551549 CAPLUS
DOCUMENT NUMBER: 101:151549
TITLE: Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene, X. Syntheses of N-alkyl- and -dialkylaminoalkanoyl derivatives of trans-2-amino-3-hydroxy-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene
AUTHOR(S): Khristova, K.; Danchev, D.
CORPORATE SOURCE: Fac. Pharm., Med. Acad., Sofia, 1000, Bulg.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1984), 317(7), 619-23
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English

10/ 071,483

GI



I

AB The amides I [R = COCH2NR1R2; R1 = H, R2 = CHMe2, CHMeEt, CMe3; R1 = R2 = Me, Et; NR1R2 = pyrrolidino, piperidino, morpholino, 4-(2-hydroxyethyl)piperazino] were prepd. by acylating I (R = H) with ClCOCH2Cl and aminating I (R = COCH2Cl). I (R = COCH2NHCMe3) had antiarrhythmic activity (no data).

IT **92311-87-0P 92311-89-2P 92311-92-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 92311-87-0 CAPLUS

CN 1-Piperidineacetamide, N-(1,2,3,4-tetrahydro-3-hydroxy-5,8-dimethoxy-2-naphthalenyl)-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 92311-89-2 CAPLUS

CN 1-Piperazineacetamide, 4-(2-hydroxyethyl)-N-(1,2,3,4-tetrahydro-3-hydroxy-5,8-dimethoxy-2-naphthalenyl)-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 92311-92-7 CAPLUS
CN 1-Piperidineacetamide, N-(1,2,3,4-tetrahydro-3-hydroxy-5,8-dimethoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1983:470648 CAPLUS
DOCUMENT NUMBER: 99:70648
TITLE: The preparation and some reactions of a tricyclic oxazinedione enol ether
AUTHOR(S): Bowman, Ralph E.
CORPORATE SOURCE: Welsh Sch. Pharm., Univ. Wales, Cardiff, CF1 3NU, UK
SOURCE: Synthetic Communications (1983), 13(2), 151-65
CODEN: SYNCAV; ISSN: 0039-7911
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 99:70648
GI



I



II



III



IV

AB The enol ether ester I was prepd. and converted to oxo ester II. Thus, III Na salt reacted with BrCH2C(OMe):CHCO2Me under N to give I; and treatment of the latter with CF3CO2H at room temp. gave II. I also underwent cleavage reactions; NH3 was added to I in EtOH to give tetralone deriv. IV.

IT **86133-97-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 86133-97-3 CAPLUS

CN 2-Butenoic acid, 4-[(aminooxoacetyl)(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)amino]-3-methoxy-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1982:582873 CAPLUS

DOCUMENT NUMBER: 97:182873

TITLE: Bicyclic compounds and their use

INVENTOR(S): Oka, Yoshikazu; Nishikawa, Kohei; Miyake, Akio

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

10/ 071,483

SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 51391	A1	19820512	EP 1981-304940	19811021
EP 51391	B1	19840905		
R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
JP 57077651	A2	19820515	JP 1980-154394	19801031
JP 62012800	B4	19870320		
JP 57179141	A2	19821104	JP 1981-64371	19810428
JP 02023538	B4	19900524		
AU 8176521	A1	19820506	AU 1981-76521	19811016
AU 543804	B2	19850502		
US 4822818	A	19830524	US 1981-312639	19811019
ZA 8107253	A	19820929	ZA 1981-7253	19811020
GB 2086393	A	19820512	GB 1981-31719	19811021
GB 2086393	B2	19840111		
AT 9220	E	19840915	AT 1981-304940	19811021
FI 8103383	A	19820501	FI 1981-3383	19811028
FI 73698	B	19870731		
FI 73698	C	19871109		
DK 8104781	A	19820501	DK 1981-4781	19811029
DK 164917	B	19920907		
DK 164917	C	19930201		
NO 8103662	A	19820503	NO 1981-3662	19811029
NO 155133	B	19861110		
NO 155133	C	19870218		
HU 28805	O	19831228	HU 1981-3176	19811029
HU 183652	B	19840528		
SU 1271372	A3	19861115	SU 1981-3350151	19811029
CA 1287444	A1	19910806	CA 1981-389042	19811029
ES 506714	A1	19830601	ES 1981-506714	19811030
ES 515269	A1	19831201	ES 1982-515269	19820826
US 4474692	A	19841002	US 1983-494061	19830512
ES 524148	A1	19850501	ES 1983-524148	19830715
CA 1287446	A2	19910806	CA 1984-468185	19841119
NO 8602859	A	19820503	NO 1986-2859	19860715
NO 157103	B	19871012		
NO 157103	C	19880120		
JP 63002963	A2	19880107	JP 1987-30000	19870212
JP 02024265	B4	19900529		
US 5098892	A	19920324	US 1989-302940	19890130

PRIORITY APPLN. INFO.:

JP 1980-154394	19801031
JP 1981-64371	19810428
US 1981-312639	19811019
EP 1981-304940	19811021
CA 1981-389042	19811029
NO 1981-3662	19811029

OTHER SOURCE(S): CASREACT 97:182873
GI

10/ 071,483



I



II



III

AB Peptide derivs. I [R, R1 = H, OH, C1-4 alkoxy; RR1 = C1-4 alkylenedioxy; R2 = H, C1-4 alkyl; R3 = H, C1-4 alkyl, (un)substituted amino-C1-4 alkyl; R4 = H, C1-4 alkyl, (un)substituted phenyl-C1-4 alkyl; R5 = OH, C1-4 alkoxy, mono- or di-C1-4 alkylamino; m, n = 1, 2] were prepd. as angiotensin-converting enzyme (ACE) inhibitors and antihypertensives. Thus, H-Gly-OEt.HCl was treated with 2-indanone in MeOH contg. NaBH3CN to give indanylglycine II, which was coupled with PhCH2O2C-Ala-OH by ClCO2CH2CHMe2 to give the protected dipeptide, which was deblocked by sapon. and hydrogenolysis to give dipeptide III (R6 = H). The latter was treated with PhCH2CH2COCO2Et in EtOH for 1 h at room temp. and the resulting soln. was reduced by NaBH3CN and then treated with HCl/EtOH to give III.HCl [R = PhCH2CH2CH(CO2Et)] (IV). IV at 1 .mu.M inhibited ACE by 87%.

IT **83402-78-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with Et oxophenylbutyrate)

RN 83402-78-2 CAPLUS

CN Glycine, N-L-alanyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1981:15427 CAPLUS

DOCUMENT NUMBER: 94:15427

TITLE: 1,3,4,5-Tetrahydrobenz[cd]indoles and related compounds. Part IV. Experiments towards the synthesis of the Ergot alkaloids and related structures. Part 2. New alkylations on .alpha.-carbon and nitrogen in .alpha.-amido ketones

AUTHOR(S): Bowman, Ralph E.

CORPORATE SOURCE: Welsh Sch. Pharm., Univ. Wales Inst. Sci. Technol., Cardiff, CF1 3NU, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999)

10/ 071,483

(1980), (10), 2126-33
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The alkylation of .alpha.-amido ketones in the 3,4-dihydronaphthalen-1(2-H)-one and -acenaphthen-5(2aH)-one series, by treatment with NaH (1 or 2 mol equiv) in DMF and subsequent reaction with alkyl halides, was examd. Acetamido derivs., e.g. I (R = Ac, R1 = R2 = H), were converted in good yield to C-alkylated products, e.g. with Me halide 76% I (R = Ac, R1 = H, R2 = Me) was obtained. Formamido ketones, e.g. I (R = CHO, R1 = R2 = H), gave complex methylation products, but with 2 mol equiv base, C,N-dimethylated ketones, e.g. I (R = CHO, R1 = R2 = Me), were obtained quant. In contrast, ketourethanes, e.g. I (R = CO2Me, R1 = R2 = H), and oxamic esters, e.g. II (R = COCO2Me, R1 = R2 = H), gave N-alkyloxazolinones and N-alkyloxazinediones, e.g. II (n = 1, 2), resp.

IT **75834-84-3P 75834-85-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 75834-84-3 CAPLUS
CN Ethanediamide, (1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 75834-85-4 CAPLUS
CN Ethanediamide, N-methyl-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1978:104971 CAPLUS
DOCUMENT NUMBER: 88:104971
TITLE: The synthesis of 2,5-diamino-6-hydroxy-1,2,3,4-tetrahydro-1-naphthalenol derivatives

10/ 071,483

AUTHOR(S): Miyake, Akio; Kuriki, Hisashi; Tada, Norio; Nishikawa, Masao; Oka, Yoshikazu
CORPORATE SOURCE: Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1977), 25(11), 3066-74
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Thirteen diaminonaphthalenols (I, R = alkyl, cycloalkyl aralkyl, heterocyclylalkyl, heterocyclyl, R1 = NH2, R2 = H) were prepd. by treating I (R = R2 = H, R1 = NH2) with the appropriate aldehydes or ketones in the presence of LiBH3CN. Most of them are potent .beta.-adrenoceptor agonists with considerable .beta.2-selectivity. However, the position isomer I (R = CHMe2, R1 = H, R2 = NH2), prepd. similarly from I (R = R1 = H, R2 = NH2), had no .beta.-adrenoceptor activity.

IT **65543-76-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 65543-76-2 CAPLUS

CN 1,6-Naphthalenediol, 5-amino-2-[(cyclohexylmethyl)amino]-1,2,3,4-tetrahydro-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

L3 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1978:104970 CAPLUS
DOCUMENT NUMBER: 88:104970
TITLE: The syntheses and .beta.-adrenoceptor activities of N-substituted 2-amino-5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthalenols

10/ 071,483

AUTHOR(S): Itoh, Katsumi; Motohashi, Michio; Kuriki, Hisashi; Sugihara, Hirosaka; Inatomi, Nobuhiro; Nishikawa, Masao; Oka, Yoshikazu
CORPORATE SOURCE: Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1977), 25(11), 2917-28
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB Tetralintriols I (R = H, C2-4 alkyl, C4-6 cycloalkyl, phenylalkyl), which exhibited .beta.-adrenoceptor activity, were prepd. from the resp. aminotetralones II and the protected triol III by known methods.

IT **65736-29-0P 65736-30-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 65736-29-0 CAPLUS
CN 1,2,5-Naphthalenetriol, 6-[(cyclohexylmethyl)amino]-5,6,7,8-tetrahydro-, hydrobromide, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HBr

RN 65736-30-3 CAPLUS
CN 1,2,5-Naphthalenetriol, 6-[(cyclohexylmethyl)amino]-5,6,7,8-tetrahydro-, hydrobromide, trans- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



● HBr

L3 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1977:121048 CAPLUS
DOCUMENT NUMBER: 86:121048
TITLE: Derivatives of 2-amino-(1,2,3,4-tetrahydronaphthalene)
INVENTOR(S): Vanhoof, Pierre M.; Clarebout, Pierre M.
PATENT ASSIGNEE(S): Christiaens, A., S. A., Belg.
SOURCE: U.S., 8 pp. Division of U.S. 3,943,172.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3984464	A	19761005	US 1974-530096	19741206
US 3943172	A	19760309	US 1973-404048	19731005
US 3981872	A	19760921	US 1974-530095	19741206

PRIORITY APPLN. INFO.:
BE 1972-46268 19721006
US 1973-404048 19731005
GB 1972-46268 19721006

GI



I

AB About 18 aminonaphthalenes I [R = H, OMe; R1 = H, Me, Et; R2 = Me, Et; or (NR1R2) = piperidino, pyrrolidino; Z = CH2, CO; n = 1,2; base or acid addn. salt, e.g., fumarate and oxalate], useful as antiarrhythmics, were prepd. Thus, .beta.-tetralol was converted to its mesylate, which was heated with PhNH2 at 130.degree.c and the product was acidified with HCl. to give 2-anilinotetralin hydrochloride (II). II was treated with NaNH2 in PhMe and then heated with Cl(CH2)3NEt2 to give I (R = H; R1 = R2 = Et; Z = CH2; n = 2) (III). Acid addn. salts of III on oral administration to rats showed antiarrhythmic activity 719% of that of procainamide.

IT **52802-35-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for use as antiarrhythmic agent)

RN 52802-35-4 CAPLUS

10/ 071,483

CN 1-Piperidineethanamine, N-phenyl-N-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 52802-34-3
CMF C24 H32 N2 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L3 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:542882 CAPLUS
DOCUMENT NUMBER: 85:142882
TITLE: Synthesis and analgesic activities of some 2-amino-1,1-dialkyl-7-methoxy-1,2,3,4-tetrahydronaphthalenes and related compounds
AUTHOR(S): Hirose, Noriyasu; Kuriyama, Shizuo; Fujimoto, Masatoshi; Toyoshima, Shoji
CORPORATE SOURCE: Res. Lab., Eisai Co., Ltd., Tokyo, Japan
SOURCE: Yakugaku Zasshi (1976), 96(2), 185-94
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB Title tetrahydronaphthylamines [I; R = Me, Et, Pr; RR = (CH2)5; R1, R2 = H, Me, Et, phenethyl, 3-phenylpropyl, cyclohexylmethyl] were prepd. in several steps from 7-methoxy-2-tetralone. Screening tests (acetic acid writhing method) showed that the analgesic activity of 2-amino-1,2,3,4-tetrahydronaphthalene is increased when geminal Et groups are introduced at the 1-position; the activity is decreased when substitution is made at the amino group. The mass spectral fragmentations

were detd. for some of the compds.

IT **60516-38-3P 60516-42-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and analgesic activity of)

RN 60516-38-3 CAPLUS
CN 2-Naphthalenamine, N-(cyclohexylmethyl)-1,1-diethyl-1,2,3,4-tetrahydro-7-methoxy-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 60516-37-2
CMF C22 H35 N O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 60516-42-9 CAPLUS
CN 2-Naphthalenamine, N-(cyclohexylmethyl)-1,2,3,4-tetrahydro-7-methoxy-1,1-dipropyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 60516-41-8
CMF C24 H39 N O



CM 2

CRN 144-62-7
CMF C2 H2 O4



10/ 071,483

IT **60516-28-1P 60516-30-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. with lithium aluminum hydride)
RN 60516-28-1 CAPLUS
CN Cyclohexanecarboxamide, N-(1,1-diethyl-1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 60516-30-5 CAPLUS
CN Cyclohexanecarboxamide, N-(1,2,3,4-tetrahydro-7-methoxy-1,1-dipropyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:420935 CAPLUS
DOCUMENT NUMBER: 85:20935
TITLE: Aminotetralin compounds
INVENTOR(S): Sugihara, Hirosada; Watanabe, Masazumi; Motohashi, Michio; Nishikawa, Masao; Sanno, Yasushi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Ger. Offen., 81 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2525923	A1	19760102	DE 1975-2525923	19750611
JP 50160250	A2	19751225	JP 1974-69457	19740617
JP 50160251	A2	19751225	JP 1974-69458	19740617
JP 50160252	A2	19751225	JP 1974-69459	19740617
JP 58026333	B4	19830602		
AU 7581942	A1	19761216	AU 1975-81942	19750609
DK 7502675	A	19751218	DK 1975-2675	19750613
ZA 7503805	A	19760526	ZA 1975-3805	19750613
BE 830298	A1	19751216	BE 1975-157380	19750616
NO 7502138	A	19751218	NO 1975-2138	19750616
SE 7506882	A	19751218	SE 1975-6882	19750616
FR 2309512	A1	19761126	FR 1975-18737	19750616
ES 438591	A1	19770701	ES 1975-438591	19750616
FI 7501794	A	19751218	FI 1975-1794	19750617
NL 7507216	A	19751219	NL 1975-7216	19750617

PRIORITY APPLN. INFO.: JP 1974-69457 19740617
JP 1974-69458 19740617
JP 1974-69459 19740617

10/ 071,483

GI



I



II



III

AB Title compds. I (R = H, or a hydrocarbyl, substituted hydrocarbyl, or acyl group; R1 and R2 = H or protective groups) and their salts, useful in a variety of pharmaceutical applications, esp. as a .beta.2-adrenergic receptor stimulator (no data), were prepd. by hydrolysis of II (all R groups have same meaning) or conversion of III (X = CO, CHOH, or CHOR4, where R4 = protective group; R3 = a protected amino group or a group such as NO, NO2, or NHOH, which can be converted to an amino group). Among approx. 90 I and/or their salts thus prepd. were (R, R1, R2 given): Ac, Me, Me; cyclopentyl, PhCH2, PhCH2; 4-MeOC6H4CH2CHMe, H, H; H, Me, Me; and Me2CHCH2, H, H.

IT **58475-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 58475-76-6 CAPLUS

CN 1,2,5-Naphthalenetriol, 6-[(cyclohexylmethyl)amino]-5,6,7,8-tetrahydro-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

L3 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:420934 CAPLUS
DOCUMENT NUMBER: 85:20934
TITLE: Aminotetralol compounds
INVENTOR(S): Sugihara, Hirosada; Watanabe, Masazumi; Motohashi, Michio; Nishikawa, Masao; Sanno, Yasushi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

10/ 071,483

SOURCE: Ger. Offen., 149 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2525512	A1	19751218	DE 1975-2525512	19750607
DE 2525512	C2	19871126		
JP 58033219	B4	19830718	JP 1974-67539	19740612
JP 50160249	A2	19751225		
JP 51125265	A2	19761101	JP 1974-137883	19741129
JP 51086456	A2	19760729	JP 1975-8148	19750117
ZA 7503647	A	19760526	ZA 1975-3647	19750605
BE 830122	A1	19751211	BE 1975-157237	19750611

PRIORITY APPLN. INFO.:

JP 1974-67539	19740612
JP 1974-123539	19741025
JP 1974-137883	19741129
JP 1975-8148	19750117

GI



I



II



III

AB Tetrahydronaphthols I (R = Me2CH, Me3C, cyclohexyl, 4-MeOC6H4CH2CHMe, etc; R1 = H, Ac, HO, NO2, CN, NH2, etc; R2 = H, PhCH2, Me; n = 0,1,2), useful as bronchodilators, were prepd. Thus, redn. of II with NaBH4 gave III. Several methods for the prepn. of starting materials and animal test procedures were described. Pharmaceutical formulations were given.

IT **59605-70-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 59605-70-8 CAPLUS
CN 1,6-Naphthalenediol, 5-amino-2-[(cyclohexylmethyl)amino]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L3 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:105281 CAPLUS
DOCUMENT NUMBER: 84:105281
TITLE: Aminotetralol compounds
INVENTOR(S): Sugihara, Hirosada; Watanabe, Masazumi; Motohashi, Michio; Nishikawa, Masao; Sanno, Yasushi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Ger. Offen., 63 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2514455	A1	19751030	DE 1975-2514455	19750403
JP 50148341	A2	19751127	JP 1974-44631	19740419
JP 50140432	A2	19751111	JP 1974-46097	19740423
JP 50142547	A2	19751117	JP 1974-47211	19740425
JP 58026332	B4	19830602		
DK 7500872	A	19751020	DK 1975-872	19750304
US 4010202	A	19770301	US 1975-555128	19750304
NO 7500835	A	19751021	NO 1975-835	19750312
AU 7579045	A1	19760916	AU 1975-79045	19750313
ES 435624	A1	19770316	ES 1975-435624	19750314
CA 1050557	A1	19790313	CA 1975-222226	19750317
FR 2267763	A1	19751114	FR 1975-9116	19750324
FR 2267763	B1	19780630		
BE 827375	A1	19750929	BE 1975-154941	19750328
AT 7502490	A	19770115	AT 1975-2490	19750402
AT 338773	B	19770912		
CH 617180	A	19800514	CH 1975-4321	19750404
NL 7504551	A	19751021	NL 1975-4551	19750416
SE 7504450	A	19751020	SE 1975-4450	19750417
FI 7501146	A	19751020	FI 1975-1146	19750417
GB 1502155	A	19780222	GB 1975-16345	19750421

PRIORITY APPLN. INFO.:
JP 1974-44631 19740419
JP 1974-46097 19740423
JP 1974-47211 19740425

GI

10/ 071,483



I



III

AB Aminotetrahydronaphthols I (R = H, Me, PhCH2; R1 = cyclohexyl, PhCH2CH2, cyclobutyl, MeOCH2CH2, PhCHMeCH2, etc.) were prepd. by the reaction of a dihydroxyaminodihydronaphthalenone with an aldehyde or ketone and hydrogenation of the intermediate. Thus, I (R = R1 = H) (II) reacted with Ph(CH2)2CHO in EtOH, followed by hydrogenation to give I (R = H, R1 = PhCH2CH2CH2). II was prepd. by the hydrogenation of III. I were useful as bronchodilators. Test data and pharmaceutical formulations were given.

IT **58475-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 58475-76-6 CAPLUS

CN 1,2,5-Naphthalenetriol, 6-[(cyclohexylmethyl)amino]-5,6,7,8-tetrahydro-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

L3 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1974:403674 CAPLUS

DOCUMENT NUMBER: 81:3674

TITLE: Antiarrhythmic N-(aminoalkyl)- and N-(aminoalkanoyl)-N-phenyl-1,2,3,4-tetrahydronaphthalenamines

INVENTOR(S): Vanhoof, Pierre; Clarebout, Pierre

PATENT ASSIGNEE(S): Manufacture de Produits Pharmaceutiques A. Christiaens S. A.

SOURCE: Ger. Offen., 29 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2349841	A1	19740411	DE 1973-2349841	19731004
DE 2349841	B2	19791129		
DE 2349841	C3	19800814		

BE 805437	A1	19740328	BE 1973-136144	19730928
ZA 7307695	A	19740828	ZA 1973-7695	19731001
CA 1020944	A1	19771115	CA 1973-182410	19731002
FR 2201891	A1	19740503	FR 1973-35524	19731004
AU 7361014	A1	19750410	AU 1973-61014	19731004
AT 7308487	A	19750715	AT 1973-8487	19731004
AT 329041	B	19760426		
DD 107903	C	19740820	DD 1973-173906	19731005
DD 108903	C	19741012	DD 1973-175710	19731005
HU 167253	P	19750927	HU 1973-CI1414	19731005
ES 419381	A1	19760401	ES 1973-419381	19731005
GB 1440440	A	19760623	GB 1972-46268	19731005
CH 585691	A	19770315	CH 1973-14285	19731005
CH 589607	A	19770715	CH 1976-13702	19731005
NL 156131	B	19780315	NL 1973-13721	19731005
JP 49092056	A2	19740903	JP 1973-112750	19731006
US 3981872	A	19760921	US 1974-530095	19741206
AT 7409956	A	19760115	AT 1974-9956	19741213
AT 332386	B	19760927		

PRIORITY APPLN. INFO.:

GB 1972-46268	19721006
AT 1973-8487	19731004
US 1973-404048	19731005

GI For diagram(s), see printed CA Issue.

AB Fourteen aminonaphthalenes I [R = H or OMe; R1 = H; R2 = NPhCO(CH2)2NHR4 or NPh(CH2)nNR3R4 with n = 2 or 3; R3 = H, Me, or Et, R4 = Me or Et, or NR3R4 = 1-pyrrolidinyl or piperidino] were prepd., mainly as salts, by reaction of I (R1 = H, R2 = NHPh) (II) with Cl(CH2)nNR3R4 or successive reaction of II with ClCO(CH2)2Cl and R4NH2, optionally followed by LiAlH4 redn. II were prepd. by NaBH4 redn. of I (R1R2 = O), reaction of the resulting I (R1 = H, R2 = OH) with ClSO2Me, and subsequent reaction with PhNH2. I had antiarrhythmic activity in rats.

IT **52802-35-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 52802-35-4 CAPLUS

CN 1-Piperidineethanamine, N-phenyl-N-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 52802-34-3
CMF C24 H32 N2 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L3 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1967:18840 CAPLUS
DOCUMENT NUMBER: 66:18840
TITLE: Derivatives of DL-1,2,3,4-tetrahydro-2-naphthylamine acylated with amino acids
AUTHOR(S): Orosz, Ferenc; Clauder, Otto; Kisfaludy, Lajos; Uskert, Emilia
CORPORATE SOURCE: Med. Univ., Budapest, Hung.
SOURCE: Acta Chimica Academiae Scientiarum Hungaricae (1966), 49(3), 291-302
CODEN: ACASA2; ISSN: 0001-5407
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Z = PhCH2O2C throughout this abstr. Dry Et3N (1.01 g.) and 1.09 g. ClCO2Et added dropwise at -20.degree. with stirring to 2.23 g. Z-Ala, m. 84-5.degree., in 25 cc. tetrahydrofuran (THF), stirred 15 min., added dropwise to 1.47 g. 1,2,3,4-tetrahydro-2-naphthyl-amine (I), stirred 10 min. at -10.degree., 20 min. at 0.degree., and 0.5 hr. at room temp., and evapd. in vacuo at 40.degree., and the residue treated with 30 cc. AcOEt and worked up gave 3.17 g. N-(Z-Ala) deriv. (II) of I, m. 148-9.degree. (aq. dioxane), [.alpha.] 20 D -3.74.degree. (c 1, EtOH). Z-Pro (2.49 g.) in 20 cc. dry dioxane treated with 1.43 cc. I and 2.16 g. dicyclohexylcarbodiimide, kept at room temp. overnight, and worked up gave 2.87 g. N-(Z-Pro) deriv. of I, m. 135-6.degree. (aq. EtOH), [.alpha.] 20 D 33.0.degree. (c 1, EtOH). I (1.47 g.) and 4.20 g. p-O2NC6H4OPhe-Z, m. 126.5.degree., in 20 cc. abs. EtOH kept 1 hr. at room temp. gave 4.07 g. N-(Z-Phe) deriv. of I, m. 121-2.degree. (aq. EtOH), [.alpha.] 20 D 7.1.degree. (c 1, EtOH). By these method were prepd. the following N-acyl derivs. of I (acyl group, % yield, m.p., and [.alpha.]D given): Z-DL-Ala, 58, 189-90.degree., -; Z-Asp(OCH2Ph), 80.5, 117-18.degree., -; Z-L-Asp(NH2), 62, 200-3.degree., 3.3.degree.; Z-Glu(NH2), 85.6, 218-19.degree., -2.2.degree.; Z-Gly, 92, 107-8.degree., -; Z-Leu, 52, 117-18.degree., -18.0.degree.; Z-Lys(Z), 73, 163-5.degree., -4.2.degree.; Z-Pro(N-Me), 86, 147.degree., -24.2.degree.; Z-Tyr, 87, 127-8.degree., -; Z-Try, 84.5, 135-6.degree., 10.2.degree.; Z-Pro-Gly, 69, 128-30.degree., 7.5.degree.; Z-Gly-Pro, 64, 138-40.degree., -61.0.degree.. I (1.47 g.) added dropwise with stirring at -10.degree. to 1.01 g. Et3N and 2.24 g. phthaloylglycyl chloride, m. 85-6.degree., in 20 cc. dry dioxane and kept at room temp. overnight gave 3.3 g. phthalimidoacetyl deriv. (III) of I, m. 228.degree. (EtOH). Z(Cl)-Pro-Leu-Gly [Z(Cl) = p-ClC6H4O2CCH2] (4.54 g.), m. 171-3.degree., in 25 cc. THF and 1.4 g. dry Et3N treated with stirring at -20.degree. with 0.96 cc. ClCO2Et yielded 3.5 g. Z(Cl)-Pro-Leu-Gly deriv. of I, m. 153-5.degree. (aq. MeOH), [.alpha.] 20 D -42.5.degree. (c 2, EtOH). Similarly were prepd. the following N-acyl derivs. of I (N-acyl group, % yield, m.p., and [.alpha.]D given): Z(Cl)-DL-Ala, 96, 187-9.degree., -; Z(Cl)-Cys(CH2Ph), 71, 130-2.degree., -9.0; Z(Cl)-Glu(NH2), 92, 197-9.degree., 15.1.degree.; Z(Cl)-Ile, 95, 171-2.degree., 14.2; Z(Cl)-Leu, 82, 164-5.degree., 7.7.degree.; Z(Cl)-Met, 57.2, 115.degree., 2.3.degree.; Z(Cl)-Val, 68.73, 178.degree., 17.5.degree.. II (2 g.) shaken with 5 cc. 30% HBr-AcOH until CO2 evolution ceased and dild. with 50 cc. dry Et2O gave 1.55 g. H-Ala deriv. (IV) of I.HBr, m. 183.degree., [.alpha.] 20 D 6.84.degree. (c 1, H2O). Z-Try deriv. (1.7 g.) of I, m. 135-6.degree., in 10 cc. abs. MeOH and 0.4 cc. concd. HCl hydrogenated over 1.7 g. prehydrogenated 10% Pd-C yielded 1.02 g. H-Try deriv. of I.HCl, m. 147-8.degree. (MeOH-Et2O), [.alpha.] 20 D 51.3.degree. (c 1, EtOH). III (3.3 g.) in 30 cc. abs. EtOH and 10 cc. M alc. N2H4.H2O refluxed 1 hr. and evapd., and the residue treated 10 min. at 50.degree. with 25 cc. 2N HBr gave 2.54 g. H-Gly deriv. of I.HBr, m. 225.degree.. By these methods were prepd. the following N-acyl derivs. of I, I.HBr, or I.HCl (amino acid providing acyl group, % yield, m.p., and [.alpha.]D given): DL-Ala (HBr), 91.5, 187-9.degree., -;

L-Asp(OCH2Ph)-(HBr), -, 170-2.degree., -; L-Asp(NH2) (HBr), 82, 126.degree., -; L-Cys(CH2Ph) (HBr), 72, 72-3.degree., 22.6.degree.; Glu(NH2) (HBr), 85, 193-4.degree., 16.5.degree.; Ile (HCl), 87, 109.degree., 21.4.degree.; Ile (HBr), 70 120.degree., 19.0.degree.; Leu (HBr), 92, 110.degree., 19.6.degree.; Lys (2HBr), 85, 161.degree., 1.35; Met (HBr), 86, 83.degree., -; Phe (HBr), 80, 155.degree., 62.0.degree.; Pro (HCl) (V), 81, 188-9.degree., -55.0.degree.; Pro (HBr), 84, 104.degree., -36.1.degree.; Pro(N-Me) (HCl), 69, 158-9.degree., -; Try (HBr), 70, 107.degree., 52.4.degree.; Val (HCl), 76, 179-80.degree., -; Val (HBr), 73, 123.degree., 12.8.degree.; Pro-Gly (HCl), 97, 144-6.degree., -22.0.degree.; Gly-Pro (HCl), 74, 227-0.degree., -45.5.degree.; Pro-Leu-Gly (HBr), 40, 220.degree., -.

IT **14329-70-5P 14329-71-6P 14329-73-8P**
14329-74-9P 14329-75-0P 14341-46-9P
14341-59-4P 14341-60-7P 14341-61-8P
14341-62-9P 14341-63-0P 14341-64-1P
14341-65-2P 14341-69-6P 14341-70-9P
14957-89-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 14329-70-5 CAPLUS

CN Indole-3-propionamide, .alpha.-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 14329-71-6 CAPLUS

CN Acetamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide, DL- (8CI) (CA INDEX NAME)



● HBr

RN 14329-73-8 CAPLUS

CN Succinamic acid, 3-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, benzyl ester, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14329-74-9 CAPLUS
CN Succinamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14329-75-0 CAPLUS
CN Propionamide, 2-amino-3-(benzylthio)-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14341-46-9 CAPLUS
CN Hydrocinnamamide, .alpha.-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrochloride (8CI) (CA INDEX NAME)



HCl

RN 14341-59-4 CAPLUS
CN Glutaramide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14341-60-7 CAPLUS
CN Valeramide, 2-amino-3-methyl-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 14341-61-8 CAPLUS
CN Valeramide, 2-amino-3-methyl-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14341-62-9 CAPLUS
CN Valeramide, 2-amino-4-methyl-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



HBr

10/ 071,483

RN 14341-63-0 CAPLUS
CN Hexanamide, 2,6-diamino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, dihydrobromide (8CI) (CA INDEX NAME)



● 2 HBr

RN 14341-64-1 CAPLUS
CN Butyramide, 2-amino-4-(methylthio)-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14341-65-2 CAPLUS
CN Hydrocinnamamide, .alpha.-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14341-69-6 CAPLUS
CN Butyramide, 2-amino-3-methyl-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 14341-70-9 CAPLUS
CN Butyramide, 2-amino-3-methyl-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14957-89-2 CAPLUS
CN Indole-3-propionamide, .alpha.-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

IT **14329-69-2 14329-72-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereoisomers)
RN 14329-69-2 CAPLUS
CN Propionamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)

10/ 071,483



● HBr

RN 14329-72-7 CAPLUS

L3 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1963:462858 CAPLUS
DOCUMENT NUMBER: 59:62858
ORIGINAL REFERENCE NO.: 59:11661b-e
TITLE: Amino acid derivatives of 1,2,3,4-tetrahydro-2-naphthylamine
INVENTOR(S): Clauder, Otto; Orosz, Ferenc; Kisfaludy, Lajos; Szporny, Laszlo
PATENT ASSIGNEE(S): Richter, Gedeon, Vegyeszeti Gyar RT
SOURCE: 6 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AT 227688		19630610	AT	
HU 149409			HU	

PRIORITY APPLN. INFO.: HU 19601110
GI For diagram(s), see printed CA Issue.
AB New derivs. of 1,2,3,4-tetrahydro-2-naphthylamine in which R3 = H or low alkyl, R, R1, and R2 are H or optionally substituted alkyl, aryl, aralkyl, or heterocyclic residues, and wherein R1 and R2 must be H if R is H, and wherein 2 of the substituents R, R1, and R2 may form a heterocyclic nucleus, and wherein R1 and R2 may also be the residue of a preferably optically active amino acid or of a peptide, and salts of these compds. are prepd. by condensing an optionally N-monoalkylated 1,2,3,4-tetrahydro-2-naphthylamine with a compd. capable of introducing an amino acid or peptide group into an amino group. The reactive groups which are not to be treated are thereby protected in a known manner, the protecting groups are removed in the condensation product, and the formed free NH2 groups may be aminoacylated to build up a peptide chain. The obtained bases may also be converted into salts. Thus, there have been prepd.: N-carbobenzoxy-L(+)-alanyltetrahydronaphthylamine, m. 146.degree., [.alpha.]20D -3.74.degree.; L(+)-alanyltetrahydronaphthylamine-HBr, m. 183.degree.; glycyltetrahydronaphthylamine-HBr, m. 225.degree.; N-carbobenzoxy-L-phenylalanyltetrahydronaphthylamine, m. 120 2.degree., [.alpha.]20D 7.2.degree.; L-phenylalanyltetrahydronaphthylamine-HCl, m. 131.degree. (HBr salt analog m. 155.degree., [.alpha.]20D 62.0.degree.); N-carbobenzoxy-L-prolyl-N-methyltetrahydronaphthylamine, m. 125.degree.; L-prolyl-N-methyltetrahydronaphthylamine-HCl, m. 175.degree.; N-p-chlorocarbobenzoxy-L-glutamyltetrahydronaphthylamine, m. 197-9.degree., L-glutamyltetrahydronaphthylamine-HBr, m. 192-4.degree.; N-carbobenzoxy - L - prolylglycyltetrahydronaphthylamine, m. 128-30.degree.; L - prolylglycyltetrahydronaphthylamine- HBr, m. 143-6.degree.. The new compds. are of pharmaceutical value.
IT **14329-69-2**, Propionamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, hydrobromide **14329-71-6**, Acetamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, hydrobromide **14341-59-4**, Glutaramide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-

10/ 071,483

, hydrobromide
(prepn. of)
RN 14329-69-2 CAPLUS
CN Propionamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

RN 14329-71-6 CAPLUS
CN Acetamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide, DL- (8CI) (CA INDEX NAME)



● HBr

RN 14341-59-4 CAPLUS
CN Glutaramide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

L3 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1963:69181 CAPLUS
DOCUMENT NUMBER: 58:69181
ORIGINAL REFERENCE NO.: 58:11862f-g
TITLE: Pharmacology of L-alanyltetrahydro-.beta.-naphthylamine
AUTHOR(S): Molnar, J.; Szporny, L.; Gorog, P.
CORPORATE SOURCE: Chem. Fabrik Gedeon Richter A.-G., Budapest, Hung.
SOURCE: Arzneimittel-Forschung (1962), 12, 1198-1200
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal

10/ 071,483

LANGUAGE: Unavailable

AB L-Alanyltetrahydro-.beta.-naphthylamine (I) in a dose of 20 mg./kg. subcutaneously caused a max. increase in motor activity in 30 min. in cats. In doses of 40 mg./kg., the max. was attained in 2.5 hrs. and some activity persisted for 7 hrs. No action on body temp. was observed. The amt. and duration of pupil expansion was proportional to the dose. In narcotized cats, 2 mg. of I/kg. caused a prompt increase in blood pressure, contraction of the nictitating membrane, but no effect on respiration. In isolated smooth muscle of guinea pigs, I did not affect spasm production by BaCl2, histamine, or acetylcholine. Inhibition of monoamine oxidase in vitro was greater than that of amphetamine and comparable with that of iproniazid. The L.D.50 in mice was 52 mg./kg. Death frequently occurred after several hrs. with tonic-clonic convulsions. Daily doses of 20 mg./kg. for 6 weeks in rats caused nervousness but no demonstrable effects in the internal organs. Wt. gain was not affected.

IT **14329-69-2**, Propionamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, hydrobromide
(pharmacology of)

RN 14329-69-2 CAPLUS

CN Propionamide, 2-amino-N-(1,2,3,4-tetrahydro-2-naphthyl)-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

L3 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1962:7606 CAPLUS

DOCUMENT NUMBER: 56:7606

ORIGINAL REFERENCE NO.: 56:1410f-h

TITLE: Tetrahydro-.beta.-naphthylamine derivatives

INVENTOR(S): Voigtlaender, Wolfgang; Wunderlich, Helmut

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 19176		19600616	DD	

AB The title products were made by treating tetrahydro-.beta.-naphthylamine (I) in the presence of aq. bases with equimolar amts. of alkylhalides. Thus, BuBr 29 was added dropwise to a stirred mixt. of I 30 in 2N NaOH 100 and the mixt. refluxed 2 hrs. and distd. to obtain N-butyltetrahydro-.beta.-naphthylamine 21 parts, b2 118-25.degree.. Similarly prepd. were the following derivs. of I: N-allyl, b2 115-21.degree.; N-tetralylglycinediethylamide, b3-4 215-23.degree.; N-tetralyl-.beta.-alaninediethylamide, b1-2 186-91.degree., N-tetralyl-N-allyl-.beta.-alaninediethylamide, b2-3 212-15.degree., N(piperidinoethyl)tetralylamine, b1 158-64.degree., N-tetralyl-N-methyl-N',N'-diethylethylenediamine, b2-3 158-63.degree..

IT **93813-67-3**, Piperidine, 1-[2-[(1,2,3,4-tetrahydro-2-naphthyl)amino]ethyl]-
(prepn. of)

RN 93813-67-3 CAPLUS

10/ 071,483

CN Piperidine, 1-[2-[(1,2,3,4-tetrahydro-2-naphthyl)amino]ethyl]- (7CI) (CA INDEX NAME)



L3 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1960:103341 CAPLUS
DOCUMENT NUMBER: 54:103341
ORIGINAL REFERENCE NO.: 54:19627i,19628a
TITLE: Bisquaternary bis(dialkylaminoethyl)-.beta.-tetralylamines
INVENTOR(S): Voigtlander, Wolfgang; Wunderlich, Helmut
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 17096		19590620	DD	

AB Sym. or unsym. bis(dialkylaminoethyl)-.beta.-tetralylamines were produced by the following reaction. Tetrahydro-.beta.-naphthylamine 30, K2CO3 30, and xylene 50 was heated with stirring and .beta.piperidinoethyl chloride 35 parts added. The mixt. was refluxed 1 hr. .beta.-Piperidinoethyl chloride 35 parts was dropped in slowly and the mixt. refluxed 2 hrs. After cooling, alkalizing, fractionating of the xylene soln. and reaction with MeI, N,N-bis(.beta.-piperidinoethyl)-.beta.-tetralylamine-2MeI, m. 246-7.degree., was obtained. The following compds. were also prepd.: N,N-bis(.beta.-diethylaminoethyl)-.beta.-tetralylamine-2MeI, m. 224-6.degree.; N-(.beta.-diethylaminoethyl)-N-(.beta.piperidinoethyl)-.beta.-tetralylamine-2MeI, 224-5.degree.. The compds. were used as drugs.

IT **103645-39-2**, Piperidine, 1-{2-[(2-diethylaminoethyl)(1,2,3,4-tetrahydro-2-naphthyl)amino]ethyl}- **121760-10-9**, Piperidine, 1,1'-[(1,2,3,4-tetrahydro-2-naphthylimino)diethylene]di- (prepn. of)

RN 103645-39-2 CAPLUS
CN Piperidine, 1-[2-[(2-diethylaminoethyl)(1,2,3,4-tetrahydro-2-naphthyl)amino]ethyl]- (6CI) (CA INDEX NAME)



RN 121760-10-9 CAPLUS
CN Piperidine, 1,1'-[(1,2,3,4-tetrahydro-2-naphthylimino)diethylene]di- (6CI) (CA INDEX NAME)

10/ 071,483



L3 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1951:52780 CAPLUS
DOCUMENT NUMBER: 45:52780
ORIGINAL REFERENCE NO.: 45:8991d-i
TITLE: Synthetic sympatholytic substances in the ergotamine series. III. New piperidyl- and morpholinyl-substituted derivatives of tetrahydro-2-naphthylamine with amine and amide functions
AUTHOR(S): Marini-Bettolo, G. B.; Chiavarelli, Stefano
CORPORATE SOURCE: Ist. super. sanita, Rome
SOURCE: Gazz. chim. ital. (1951), 81, 98-105
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB A series of N-(1-piperidyl) and N-(4-morpholinylacyl) derivs. of 1,2,3,4-tetrahydro-2-naphthylamine, ArNH2 (Ar = 2-C10H11) (X), are prepd. similarly as described in the preceding abstr. from ArNHCOCH2Cl (XI) and ArNHCO(CH2)2Cl (XII) with piperidine (XIII), 2-methylpiperidine (XIV), 2,3-dimethylpiperidine (XV), and morpholine (XVI), resp. To 30 g. X in 110 cc. 10% NaOH is added 30 g. VI at -10.degree. to give 26 g. XI, m. 121.degree. (from H2O and EtOH). The following derivs. of X of the general type ArNHX, where X is a 1-piperidyl- or 4-morpholinyl acyl group, are prepd. (X given): C5H10NCH2CO (XVII), white needles, m. 93.degree. (from dil. EtOH), [methiodide, white needles, m. 174.degree. (from EtOH-Et2O), sol. in hot EtOH, sparingly sol. in cold EtOH]; 2-MeC5H9NCH2CO, oil, b6 220.degree.; 2,3-Me2C5H8NCH2CO, oil, b0.8 196.degree.. From ArNMeCOCH2Cl (XVIII) and XIII is obtained ArNMeCOCH2NC5H10, needles, m. 75-8.degree. (from Et2O or dil. EtOH); from ArNEtCOCH2Cl and XIII ArNEtCOCH2NC5H10, b0.2 190-1.degree., m. 80-1.degree., analyzed as the reineckate. Similarly are prepd. the following ArNHX (X given): from XII and XIII C5H10N(CH2)2CO, b0.6 208-10.degree. [methiodide, sinters at 207-10.degree.; picrate, m. 132.degree.]; from XII and XIV 2-MeC5H9N(CH2)2CO, oil, b5 240-5.degree.; from XII and XV 2,3-Me2C5H8N(CH2)2CO, b0.2 180-210.degree.; from XVIII and XV, ArNMeCO(CH2)2NC5H8Me2, b0.4 173-5.degree.; from 1-(chloroacetyl)piperidine (XIX) (obtained from XIII and VI in 8% aq. NaOH at -10.degree.) and X, ArNHCH2COC5H11, oil, b0.4 198.degree., analyzed as the reineckate, decomp. 195.degree.; from ArNHMe (XX) and XIX ArNMeCH2CONC5H10, b0.5 216-20.degree., analyzed as the reineckate; from ArNHEt (XXI) and XIX, ArNEtCH2CONC5H10, b1 222-32.degree.. XIII (15 g.) and 23 g. Br(CH2)2COCl in 90 cc. 8% aq. NaOH are kept 0.5 hr. at room temp., then extd. with Et2O, and the ext. washed successively with H2O, dil. HCl, 2% aq. Na2CO3, and H2O, dried with Na2SO4, and distd. to give C5H10NCO(CH2)2Br (XXII), oil, b6 145-7.degree., n20D 1.5285. Similarly as above are prepd.: from XXII and X, ArNH(CH2)2CONC5H10, b0.5 205-8.degree., f.p. 90.degree.; from XXII and XX, ArNMe(CH2)2COC5H10, oil, b0.5 216-20.degree.; from XI and XVI, ArNHCOCH2N.(CH2)2.O.CH2.CH2, white

10/ 071,483

needles, m. 102.degree. (from Et2O); from XVIII and XVI, ArNMeCOCH2N.(CH2)2.O.CH2.CH2, b0.6 197-9.degree., f.p. 58.degree.; from XII and XVI, ArNHCO(CH2)2N.(CH2)2.O.CH2.CH2, white tablets, m. 112.degree. (from Et2O), b0.4 198-203.degree.. Reduction of XVII with LiAlH4 in C6H6-Et2O gives ArNH(CH2)2NC5H10, b2.5 230.degree..

IT **93813-67-3**, Piperidine, 1-[2-(1,2,3,4-tetrahydro-2-naphthylamino)ethyl]-
(prepn. of)

RN 93813-67-3 CAPLUS

CN Piperidine, 1-[2-[(1,2,3,4-tetrahydro-2-naphthyl)amino]ethyl]- (7CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:04:02 ON 07 JUN 2003)

FILE 'REGISTRY' ENTERED AT 10:04:07 ON 07 JUN 2003
L1 STRUCTURE UPLOADED
L2 362 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:04:46 ON 07 JUN 2003
L3 42 S L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	193.01	341.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-27.34	-27.34

STN INTERNATIONAL LOGOFF AT 10:08:10 ON 07 JUN 2003

C:\STNEXP4\QUERIES\10071483a.str

L1:





chain nodes :
11 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
7-11 8-18 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
8-18
exact bonds :
5-7 6-10 7-8 7-11 8-9 9-10 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

C:\STNEXP4\QUERIES\10071483b.str

L2:





chain nodes :
9 16 20 21 25 34
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 22 26 27 28 29 30
chain bonds :
7-9 8-16 9-10 16-20 20-21 20-25 21-22 28-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 10-11 10-15 11-12 12-13 13-14 14-15 22-26
22-30 26-27 27-28 28-29 29-30
exact/norm bonds :
7-9 8-16 9-10 16-20 20-21 20-25 21-22 28-34
exact bonds :
5-7 7-8 22-26 22-30 26-27 27-28 28-29 29-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 : 22 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 20:CLASS 21:CLASS 22:CLASS 25:CLASS
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 34:CLASS

C:\STNEXP4\QUERIES\10071483c.str





chain nodes :
12 13 14 15 28 29 30
ring nodes :
1 2 3 4 5 6 8 9 10 11 16 17 18 19 20 21 22 23 24 25 26 27
chain bonds :
9-12 12-13 13-14 13-15 25-28 29-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-8 6-11 8-9 9-10 10-11 16-17 16-21 17-18 18-19
19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
9-12 12-13 13-14 13-15 25-28 29-30
exact bonds :
5-8 6-11 8-9 9-10 10-11 16-17 16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24
24-25 25-26 26-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 16 : 22 :

G1:H,O

G2:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS 29:CLASS 30:CLASS

10/ 071,483

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 43	Jun 06	PASCAL enhanced with additional data

10/ 071,483

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:54:55 ON 07 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:55:03 ON 07 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 JUN 2003  HIGHEST RN 526915-11-7
DICTIONARY FILE UPDATES:   6 JUN 2003  HIGHEST RN 526915-11-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10071483a.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading 10071483b.str

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

10/ 071,483

=>
Uploading 10071483c.str

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 09:56:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7642 TO ITERATE

100.0% PROCESSED 7642 ITERATIONS 132 ANSWERS
SEARCH TIME: 00.00.01

L4 132 SEA SSS FUL L1

=> s l2 ful
FULL SEARCH INITIATED 09:56:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 50 TO ITERATE

100.0% PROCESSED 50 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L2

=> s l3 ful
FULL SEARCH INITIATED 09:56:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1055 TO ITERATE

100.0% PROCESSED 1055 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 444.85 445.06

FILE 'CAPLUS' ENTERED AT 09:57:15 ON 07 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Jun 2003 VOL 138 ISS 24

10/ 071,483

FILE LAST UPDATED: 6 Jun 2003 (20030606/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4
L7 4 L4

=> d l7 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:101127 CAPLUS
DOCUMENT NUMBER: 134:162920
TITLE: Preparation of aromatic amines and amides as ligands for neuropeptide Y Y5 receptors useful in the treatment of obesity and other disorders
INVENTOR(S): Dax, Scott L.; Mcnally, James; Youngman, Mark
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009120	A1	20010208	WO 2000-US20482	20000727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6380224	B1	20020430	US 2000-626856	20000727
EP 1202986	A1	20020508	EP 2000-952233	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000012804	A	20020806	BR 2000-12804	20000727
JP 2003506367	T2	20030218	JP 2001-514323	20000727
NO 2002000384	A	20020322	NO 2002-384	20020124
US 2002115715	A1	20020822	US 2002-71483	20020207

PRIORITY APPLN. INFO.: US 1999-146069P P 19990728
US 2000-626856 A3 20000727
WO 2000-US20482 W 20000727

OTHER SOURCE(S): MARPAT 134:162920
GI



I

Applicant's pregrant pub version

10/ 071,483

AB Title compds. [I; R1 = H, OH, halo, trifluoroalkyl, cycloalkyl, NO2, amino, (substituted) alkyl, alkoxy, alkylthio, etc.; n = 1, 2; m = 0-3; B1, B2 = H; B1B2 = CH2; R2 = H, OH, halo, alkyl, alkenyl, cycloalkyl, (substituted) Ph, naphthyl, PhO, heteroaryl, heterocyclyl; L = alkylene, alkenylene, alkynylene, cycloalkylene, arylalkylene, .alpha.-aminoalkylene, piperidin-4-ylmethylene, piperazine-1-ylmethylene, etc.; Y = CH2, CO; Z = aryl, sulfonamido, arylsulfonamido, arylamido, arylureido, arylacetamido, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl], were prepd. Thus, 1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthaleneamine bishydrochloride (prepn. given), N.alpha.-tert-butoxycarbonyl-N.omega.-2-fluorobenzenesulfonyl-L-lysine (prepn. given), diisopropylethylamine, and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate were stirred in DMF to give the amide coupling product as a mixt. of diastereomers. The mixt. was deprotected with CF3CO2H followed by redn. with BH3.THF to give N-[5-amino-6-[[cis-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluorobenzenesulfonamide trihydrochloride. The latter at 3 .mu.M gave 100% inhibition of binding of 125I-PYY binding to human NPY Y5 receptors.

IT **261715-55-3P 261715-56-4P 261715-57-5P**
261715-58-6P 261715-72-4P 324755-30-8P
324755-31-9P 324755-32-0P 324755-33-1P
324755-34-2P 324755-35-3P 324755-36-4P
324755-37-5P 324755-38-6P 324755-39-7P
324755-46-6P 324755-47-7P 324755-48-8P
324755-49-9P 324755-50-2P 324755-51-3P
324755-52-4P 324755-53-5P 324755-54-6P
324755-55-7P 324755-56-8P 324755-57-9P
324755-58-0P 324755-59-1P 324755-60-4P
324755-61-5P 324755-67-1P 324755-68-2P
324755-69-3P 324755-70-6P 324755-71-7P
324755-73-9P 324755-87-5P 324755-88-6P
324755-89-7P 324755-90-0P 324755-91-1P
324755-92-2P 324755-93-3P 324755-94-4P
324755-95-5P 324755-96-6P 324755-97-7P
324756-12-9P 324756-13-0P 324756-14-1P
324756-15-2P 324756-16-3P 324756-17-4P
324756-18-5P 324756-19-6P 324756-20-9P
324756-21-0P 324756-22-1P 324756-23-2P
324756-24-3P 324756-25-4P 324756-26-5P
324756-27-6P 324756-28-7P 324756-29-8P
324756-30-1P 324756-31-2P 324756-32-3P
324756-33-4P 324756-34-5P 324756-36-7P
324756-37-8P 324756-38-9P 324756-39-0P
324756-44-7P 324756-45-8P 324756-46-9P
324756-48-1P 324756-49-2P 324756-50-5P
324756-75-4P 324756-76-5P 324756-77-6P
324757-32-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. amines and amides as ligands for neuropeptide Y Y5 receptors useful in the treatment of obesity and other disorders)

RN 261715-55-3 CAPLUS

CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylsulfonyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-56-4 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-57-5 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-58-6 CAPLUS

10/ 071,483

CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-72-4 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-30-8 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-31-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-32-0 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/ 071,483

RN 324755-33-1 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-34-2 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-35-3 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylacetyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-36-4 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-4-piperidinyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-37-5 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-4-piperidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-38-6 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[[(phenylamino)carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-39-7 CAPLUS
CN 1-Piperidineacetamide, 4-(benzoylamino)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-46-6 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-47-7 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-48-8 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



RN 324755-49-9 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-50-2 CAPLUS
CN Benzenesulfonamide, N-[5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-51-3 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(3-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-52-4 CAPLUS
CN Hexanamide, 2-[(aminocarbonyl)amino]-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-53-5 CAPLUS
CN Hexanamide, 2-(dimethylamino)-6-[(phenylsulfonyl)amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-54-6 CAPLUS
CN Hexanamide, 2-(dimethylamino)-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-55-7 CAPLUS
CN Hexanamide, 2-(dimethylamino)-6-[(phenylsulfonyl)amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-56-8 CAPLUS
CN Hexanamide, 2-(dimethylamino)-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324755-57-9 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-acetamide, 4-oxo-1-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-58-0 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-59-1 CAPLUS
CN 1-Piperidineacetamide, 4-acetyl-4-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-60-4 CAPLUS
CN 1-Piperazineethanamine, 4-(2-methoxyphenyl)-N-[(1R,2S)-1,2,3,4-tetrahydro-

10/ 071,483

1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-61-5 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-acetamide, 4-oxo-1-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-67-1 CAPLUS
CN 1-Pyrrolidineacetamide, 3-[(phenylacetyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-68-2 CAPLUS
CN Carbamic acid, [1-[2-oxo-2-[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-

pyridinylmethyl)-2-naphthalenyl]amino]ethyl]-3-pyrrolidinyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-69-3 CAPLUS
CN Carbamic acid, [1-[2-oxo-2-[[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]ethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-70-6 CAPLUS
CN 1-Pyrrolidineacetamide, 3-[[(phenylamino)carbonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-71-7 CAPLUS
CN 1-Pyrrolidineacetamide, 3-(benzoylamino)-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-73-9 CAPLUS
CN 1-Pyrrolidineacetamide, 3-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324755-87-5 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 324755-88-6 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl

RN 324755-89-7 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl

RN 324755-90-0 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 324755-91-1 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 324755-92-2 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-56-4
CMF C28 H31 F N4 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 324755-93-3 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-94-4 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-95-5 CAPLUS
CN 1-Piperidineacetamide, 4-acetyl-4-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-96-6 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-acetamide, 4-oxo-1-phenyl-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324755-97-7 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 324756-12-9 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-13-0 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-14-1 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-15-2 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-16-3 CAPLUS
CN Hexanamide, 2-amino-6-[(phenylsulfonyl)amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-17-4 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-18-5 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-19-6 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-20-9 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-21-0 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-22-1 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-23-2 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-24-3 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[(phenylsulfonyl)amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-25-4 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[(phenylsulfonyl)amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-26-5 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-27-6 CAPLUS
CN Benzamide, N-[(1S)-5-[(phenylsulfonyl)amino]-1-[[[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-28-7 CAPLUS
CN Hexanamide, 2-[[(ethylamino)carbonyl]amino]-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-29-8 CAPLUS
CN Hexanamide, 2-[(aminoiminomethyl)amino]-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-30-1 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-31-2 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-32-3 CAPLUS
CN 1-Piperidineacetamide, 4-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-33-4 CAPLUS
CN 1-Piperidineacetamide, 4-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-34-5 CAPLUS
CN 1-Piperidineacetamide, 4-[[(phenylamino)carbonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-36-7 CAPLUS
CN 1-Piperidineacetamide, 4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-37-8 CAPLUS
CN Carbamic acid, [(3S)-1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-38-9 CAPLUS
CN Carbamic acid, [(3R)-1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-39-0 CAPLUS
CN 1-Pyrrolidineacetamide, 3-(benzoylamino)-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 324756-44-7 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-45-8 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-amino-6-[[6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-46-9 CAPLUS
CN Benzenesulfonamide, N-[(5S)-5-(ethylamino)-6-[[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-48-1 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-49-2 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-50-5 CAPLUS
CN Hexanamide, 2-[[(phenylamino)carbonyl]amino]-6-[(phenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 324756-75-4 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 324756-18-5
CMF C29 H35 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 324756-76-5 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 324756-19-6
CMF C29 H35 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 324756-77-6 CAPLUS
CN Hexanamide, 2-(acetylamino)-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1S,2R)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 324757-32-6 CAPLUS
CN Benzenesulfonamide, N-[5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **247936-70-5P 261715-74-6P 324756-02-7P 324756-03-8P 324756-78-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. amines and amides as ligands for neuropeptide Y Y5 receptors useful in the treatment of obesity and other disorders)

RN 247936-70-5 CAPLUS
CN 2-Naphthalenamine, 1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-, dihydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 261715-74-6 CAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-73-5
CMF C22 H27 F N4 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 324756-02-7 CAPLUS
CN Carbamic acid, [(1S)-5-[[(2-fluorophenyl)sulfonyl]amino]-1-[[[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/ 071,483

Absolute stereochemistry.



RN 324756-03-8 CAPLUS
CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-, dihydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 324756-78-7 CAPLUS
CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-72-4
CMF C27 H35 F N4 O3

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:241159 CAPLUS
DOCUMENT NUMBER: 132:278996
TITLE: Preparation of N-aralkyl-2-tetralinamines as neuropeptide Y Y5 receptor ligands
INVENTOR(S): Dax, Scott L.; Lovenberg, Timothy W.; Baxter, Ellen W.; Carson, John R.; Ludovici, Donald W.; Youngman, Mark A.
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020376	A1	20000413	WO 1999-US23259	19991006
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346363	AA	20000413	CA 1999-2346363	19991006
AU 9962923	A1	20000426	AU 1999-62923	19991006

D.I.E.

10/ 071,483

US 6201025	B1	20010313	US 1999-413292	19991006
EP 1119543	A1	20010801	EP 1999-950218	19991006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9914360	A	20011120	BR 1999-14360	19991006
JP 2002526521	T2	20020820	JP 2000-574494	19991006
NO 2001001721	A	20010605	NO 2001-1721	20010405

PRIORITY APPLN. INFO.: US 1998-103446P P 19981007
WO 1999-US23259 W 19991006

OTHER SOURCE(S): MARPAT 132:278996

GI



I

AB R2CH2ZNHZ3R3 [I; R2 = H, halo, alkyl, (hetero)aryl, etc.; R3 = alkyl, alkoxyalkoxy, (hetero)aryl, etc.; Z = (un)substituted 1,2,3,4-tetrahydro-1,2-naphthylene; Z3 = alk(en)ylene, alkynylene, alkylenecycloalkylene] were prepd. Thus, the pyrrolidine enamine of 6-methoxy-2-tetralone (prepn. given) was alkylated by PhCH2Br and the product reductively aminated by H2NCH2CH2C6H3(OMe)2-3,4 to give title compd. cis-II. Data for biol. activity of I were given.

IT **263714-16-5P 263714-23-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aralkyl-2-tetralinamines as neuropeptide Y Y5 receptor ligands)

RN 263714-16-5 CAPLUS

CN 2-Naphthalenamine, N-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-, dihydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



2 HCl

RN 263714-23-4 CAPLUS

CN 2-Naphthalenamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-1-

10/ 071,483

(3-pyridinylmethyl)-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **263714-32-5P 263714-33-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-aralkyl-2-tetralinamines as neuropeptide Y Y5 receptor ligands)

RN 263714-32-5 CAPLUS
CN 2-Naphthalenamine, 1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-, dihydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 263714-33-6 CAPLUS
CN Benzamide, 3,4-dimethoxy-N-[(1R,2S)-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:44072 CAPLUS
DOCUMENT NUMBER: 132:236840
TITLE: .alpha.-Substituted N-(Sulfonamido)alkyl-.beta.-aminotetralins: Potent and Selective Neuropeptide Y Y5 Receptor Antagonists
AUTHOR(S): Youngman, Mark A.; McNally, James J.; Lovenberg, Timothy W.; Reitz, Allen B.; Willard, Nicole M.; Nepomuceno, Diane H.; Wilson, Sandy J.; Crooke, Jeffrey J.; Rosenthal, Daniel; Vaidya, Anil H.; Dax, Scott L.
CORPORATE SOURCE: Drug Discovery The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SOURCE: Journal of Medicinal Chemistry (2000), 43(3), 346-350
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Title compds. such as I (X = H2) were prepd. from .beta.-aminotetralins via the amides, e.g., I (X = O). The products were shown to be potent and selective antagonists of the human Y5 receptor and may be useful for treating feeding disorders and obesity.

IT **261715-50-8P 261715-51-9P 261715-52-0P 261715-53-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 261715-50-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

10/ 071,483

Relative stereochemistry.



RN 261715-51-9 CAPLUS
CN Cyclohexanecarboxamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[[(phenylsulfonyl)amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-52-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-53-1 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **247935-14-4P 247936-18-1P 247936-30-7P**
261715-55-3P 261715-56-4P 261715-57-5P
261715-58-6P 261715-59-7P 261715-60-0P
261715-61-1P 261715-62-2P 261715-63-3P
261715-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 247935-14-4 CAPLUS

CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-18-1 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-30-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-55-3 CAPLUS
CN 1-Piperidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-4-[(phenylsulfonyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-56-4 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-57-5 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-58-6 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-3-[(phenylsulfonyl)amino]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-59-7 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-,

10/ 071,483

(2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-60-0 CAPLUS
CN Benzenesulfonamide, N-[6-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-61-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-62-2 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-63-3 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-65-5 CAPLUS
CN Benzenesulfonamide, N-[(5R)-5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **261715-67-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)
RN 261715-67-7 CAPLUS
CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

IT **261715-66-6P 261715-72-4P 261715-74-6P**
261715-76-8P 261715-78-0P 261715-80-4P
261715-81-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(.alpha.-substituted N-(sulfonamido)alkyl-.beta.-aminotetralins as neuropeptide Y5 receptor antagonists)

RN 261715-66-6 CAPLUS

CN 2-Naphthalenamine, 1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 261715-72-4 CAPLUS

CN Carbamic acid, [1-[2-[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]-2-oxoethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 261715-74-6 CAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-, rel-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-73-5
CMF C22 H27 F N4 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 261715-76-8 CAPLUS
CN Carbamic acid, [5-[[(2-fluorophenyl)sulfonyl]amino]-1-[[[1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 261715-78-0 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2R)-rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-77-9
CMF C29 H35 F N4 O4 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 261715-80-4 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, (2S)-rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 261715-79-1
CMF C29 H35 F N4 O4 S

10/ 071,483

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 261715-81-5 CAPLUS
CN Benzenesulfonamide, N-[(5R)-5-amino-6-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl]-2-fluoro-, trihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:708732 CAPLUS
DOCUMENT NUMBER: 131:310453
TITLE: Preparation of N-substituted aminotetralins as neuropeptide Y5 receptor ligands
INVENTOR(S): Dax, Scott L.; Lovenberg, Timothy Walter; McNally, James J.; Reitz, Allen B.; Youngman, Mark Andrew

10/ 071,483

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955667	A1	19991104	WO 1999-US7971	19990412
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9936400	A1	19991116	AU 1999-36400	19990412
US 6140354	A	20001031	US 1999-290651	19990412
BR 9910583	A	20010109	BR 1999-10583	19990412
EP 1076644	A1	20010221	EP 1999-918500	19990412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ZA 9902951	A	20001026	ZA 1999-2951	19990426
BG 104877	A	20010629	BG 2000-104877	20001023

PRIORITY APPLN. INFO.: US 1998-83415P P 19980429
US 1999-290651 A 19990412
WO 1999-US7971 W 19990412

OTHER SOURCE(S): MARPAT 131:310453
GI



I

AB Title compds. [I; R1 = H or 1 or 2 of halo, alkoxy, Ph, etc.; R4 = (CH2)0-3R2; R2 = H, halo, alkyl, Ph, etc.; R5,R6 = H or (halo)alkyl; R7 = NHZNHSO2R3; R3 = (cyclo)alkyl, Ph, heteroaryl, etc.; Z = (cycloalkylene-interrupted) alk(en)ylene, -alkynylene] were prepd. Thus, 6-methoxy-.beta.-tetralone was condensed with pyrrolidine and the product alkylated by PhCH2Br to give, after hydrolysis, I (R1 = 6-MeO, R4 = CH2Ph, R5 = H)(II; R6R7 = O) which was reductively aminated and the product amidated by trans-4-(2-naphthylsulfonamidomethyl)cyclohexanecarboxylic acid to give, after redn., (1.alpha.,2.alpha.,trans)-II (R6 = H, R7 = NHCH2Z1CH2NHSO2R3, R3 = 2-naphthyl, Z1 = 1,4-cyclohexylene). Data for biol. activity of I were given.

IT **247935-04-2P 247935-11-1P 247935-14-4P**
247935-67-7P 247935-86-0P 247935-87-1P
247936-18-1P 247936-23-8P 247936-24-9P
247936-25-0P 247936-26-1P 247936-27-2P
247936-28-3P 247936-30-7P 247936-35-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-substituted aminotetralins as neuropeptide Y5 receptor

ligands)
RN 247935-04-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247935-11-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247935-14-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-67-7 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-86-0 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247935-87-1 CAPLUS
CN Benzenesulfonamide, N-[4-[[[1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]- (9CI) (CA INDEX NAME)



RN 247936-18-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-23-8 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-24-9 CAPLUS
CN Benzenesulfonamide, 2,6-difluoro-N-[[trans-4-[[[(1R,2S)-6-fluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-25-0 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6,7-difluoro-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2,4-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-26-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-7-fluoro-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-27-2 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-7-fluoro-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-28-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(1R,2S)-6-amino-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-30-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-35-2 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-methyl-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **247936-89-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-substituted aminotetralins as neuropeptide Y5 receptor ligands)
RN 247936-89-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]methyl]cyclohexyl]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

IT **247936-70-5P 247936-71-6P 247936-72-7P**
247936-73-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-substituted aminotetralins as neuropeptide Y5 receptor ligands)
RN 247936-70-5 CAPLUS
CN 2-Naphthalenamine, 1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-, dihydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247936-71-6 CAPLUS
CN Carbamic acid, [[trans-4-[[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]carbonyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247936-72-7 CAPLUS
CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, dihydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



2 HCl

RN 247936-73-8 CAPLUS

10/ 071,483

CN Cyclohexanecarboxamide, 4-[[(2-naphthalenylsulfonyl)amino]methyl]-N-[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:54:55 ON 07 JUN 2003)

FILE 'REGISTRY' ENTERED AT 09:55:03 ON 07 JUN 2003
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 STRUCTURE UPLOADED
L4 132 S L1 FUL
L5 0 S L2 FUL
L6 0 S L3 FUL

FILE 'CAPLUS' ENTERED AT 09:57:15 ON 07 JUN 2003
L7 4 S L4

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.98	464.04
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

STN INTERNATIONAL LOGOFF AT 09:58:34 ON 07 JUN 2003